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Macromolecular X-ray crystallography was used for structural characterization of 
enzymes involved in thiamin biosynthetic and uridine salvage pathways.  The 
enzymes involved in major metabolic pathways are potential drug targets and 
understanding their structural features and active site details lead to development of 
effective inhibitors.  THI6 is a bifunctional enzyme present in the eukaryotic thiamin 
biosynthetic pathway.  The N-terminal domain of this enzyme catalyses the ligation of 
the thiamin thiazole and pyrimidine moieties to form thiamin phosphate and the C-
terminal domain catalyzes the phosphorylation of 4-methyl-5-(hydroxyethyl)thiazole 
in a salvage pathway.  In lower organisms, thiamin phosphate synthase and 4-methyl-
5-(hydroxyethyl)thiazole kinase are separate gene products.  Current work reports the 
first crystal structure of a eukaryotic THI6 along with several complexes that 
characterize the active sites responsible for the two chemical reactions.  THI6 from 
Candida glabrata is a homehexamer in which the six protomers form a cage like 
structure.  Two domains within a protomer interact via two loop regions not found in 
the bacterial enzymes.  The structures of different protein-ligand complexes define the 
active sites of the two domains.  Our structural studies reveal that the active sites of 
the two domains are 40 Å apart and are not connected by an obvious channel.   
  The present work also includes structural and biochemical characterization of 
THI1 from Zea maize, a thiazole synthase involved in eukaryotic thiamin biosynthetic 
pathway.  The structural work was performed to investigate the role of the residue 
Val211 in this particular enzyme, as genetic mapping showed that Val211Met 
mutation resulted in a phenotype called Bladekiller 1.   In this phenotype plants 
develop some unusual characteristics, such as poor development of leaf blades, 
premature termination of meristems etc.  The three dimensional structure of the wild-
type enzyme in a complex form with the product have been described.  Biochemical 
assays reveal that the wild type enzyme purified with the bound metabolites but the 
mutant does not.  The dynamic light scattering studies show that the wild type enzyme 
forms an octamer in solution state unlike the mutant enzyme. 
 Finally the three dimensional structure of uridine phosphorylase, a key enzyme 
in the pyrimidine salvage pathway was described with the formation of glycal in its 
active site.  This enzyme catalyzes the reversible phosphorolysis of uridine to uracil 
and ribose 1-phosphate (or 2′-deoxyuridine to 2′-deoxyribose 1-phosphate).  The 
reaction is believed to proceed via an oxocarbenium ion-like transition state.  The 
reported structures include Escherichia coli uridine phosphorylase treated with 5-
fluorouridine and sulfate and dimeric bovine uridine phosphorylase treated with 5-
fluoro-2′-deoxyuridine or uridine, plus sulfate.  In each case the electron density 
shows three separate species corresponding to the pyrimidine base, sulfate and a 
ribosyl species. NMR time course studies demonstrated that uridine phosphorylase can 
catalyze the hydrolysis of these fluorinated nucleosides in the absence of phosphate or 
sulfate. Crystallization with the hydrolysis products in the presence of sulfate is then 
proposed to result in the anti-elimination of water across the C1-C2 bond of UPase-
bound ribose. In the structures of the glycal complexes the fluorouracil O2 atom is 
appropriately positioned to act as the general base required for this elimination 
reaction. Crystals of bovine uridine phosphorylase treated with 2′-deoxyuridine and 
sulfate show intact nucleoside. This nucleoside is unactivated toward cleavage of the 
N-ribosyl bond in the absence of phosphate. These results add a previously-
unencountered mechanistic motif to the body of information on glycal formation 
catalyzed by enzymes which catalyze the cleavage of glycosyl bonds. 
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CHAPTER 1 
INTRODUCTION 
Overview of Structural Biology.  Proteins are macromolecules that play major 
role in every central process of life, including catalyzing an extraordinary range of 
chemical reactions, composing the structural support of the cell, controlling membrane 
permeability, regulating the concentration of metabolites, causing motion and 
controlling the gene function.  The structural study of these macromolecules at atomic 
resolution provides key insight into the aspects of their function and leads to the 
understanding of the underlying mechanisms of action.  The field of structural biology 
is dedicated to this interrelationship between the structure and function of these 
macromolecules.  In recent years, the remarkable development in the field of structural 
biology is also showing the way for a deeper understanding of evolution and the 
complex biological systems that governs cellular function. 
The physical interactions studied in the field of structural biology are diverse.  
These levels include understanding the intramolecular interactions in macromolecules, 
leading to the proper folding from a polypeptide chain to secondary, tertiary and 
quaternary structures.  Structural data also illuminates the interaction between the 
macromolecules and small molecules, including enzyme-substrate, transporter-
metabolite and receptor-hormone interactions.  Current progress in the field has 
extended the level of study of macromolecular assemblies including the study of 
protein-protein, protein-nucleic acid complexes. 
One of the major goals of structural biology is to understand the catalytic 
reactions performed by enzymes.  The structural details at atomic level provide 
information of the enzyme active site along with the identification of the active site 
residues.  The three dimensional structure of enzymes with substrate, product and 
intermediate analogues provide the snapshots along the reaction coordinate.  Structural 
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studies combined with biochemical assays and biophysical techniques can lead to the 
complete elucidation of the underlying mechanism in enzyme catalysis.  The idea of 
transition-state formation by enzymes, was first recognized by Pauling in the year 
1946 (1).  20 years after that Jencks established a fundamental connection between 
binding energy and enzyme catalysis (2). The success in the field of enzymology has 
been astounding in the past years.  With the sufficient understanding of enzyme active 
sites and bioorganic chemistry the mechanism of numerous chemical transformations 
have been unraveled. 
Another important application of structural biology is identification of several 
enzymes as drug target allowing for rational drug design.  The three dimensional 
structure of a drug target and its interaction with the small molecule is used as a guide 
towards the drug-designing followed by optimization and virtual screening (3, 4).  
Current drug targets include not only enzymes, but also receptors, ion-channels, 
transporters and nucleic acids.  A classic example was designing drugs against HIV 
protease, a key enzyme in the life cycle of HIV (4).  Another example is discovery of 
Thymitaq®, a new treatment for liver cancer (5). 
X-ray Crystallography as a Tool for Characterizing  Enzymes.   X-ray 
crystallography is considered to be one of the most powerful techniques in studying 
the three dimensional structure of a wide variety of macromolecules at atomic level.  
The field has been evolved in the last fifty years with the development of suitable 
instrumentations and computer programs.  The first diffraction image from a protein 
crystal of pepsin was recorded in 1934 (6) and the protein structure solved was 
myoglobin in 1957, at 6 Å (7).  The present statistics shows that to date about 64,500 
protein structures have been solved including approximately 10,000 unique structures.  
The significant increase in the rate of solving structures is due to major advancement 
in the field of computer science, physics, material science and molecular and cell 
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biology.   In the recent years the field of X-ray crystallography has also been playing a 
vital role in the work of Nobel laureates.  Recenyly in 2009, the Nobel prize in 
chemistry was awarded to Ada E. Yonath, Thomas A. Steitz and Venkatraman 
Ramakrishnan for the detailed mapping of the ribosome  using X-ray crystallographic 
techniques (8).  The 2007 Nobel prize was rewarded to Roger Kornberg for his work 
on “the molecular basis of eukaryotic transcription”, which included the X-ray 
structure of RNA polymerase II in complex with different transcription factors (9) .  In 
2003, the Nobel prize was given to Roderick Mackinnon and Peter Agre for the X-ray 
crystals of potassium and water channels respectively (10, 11).   
The use of synchrotron radiation as the source for the experiments in X-ray 
crystallography provides highly coherent brilliance with tunable frequency.  The 
application of new technology in building detectors with fast read out time, low noise 
and good spatial resolution has also improved the quality of experiments (12).  The 
vast collection of computer programs used in data processing, phasing of anomalous 
data, molecular replacement, model building and refinement has been developing 
sharply with the availability for academic use. 
Current Challenges in X-ray Crystallography.  However there are few key 
challenges remaining in the field.  The main one being production of good diffraction 
quality crystals, which is an intrinsic property of the protein.  This problem has been 
approached in multiple ways such as, extensive high throughput screening, mutation 
of putative surface residues to reduce entropic effects, truncation of the terminal 
domains, chemical crosslinking etc.  The most effective method is screening of 
different orthologues of a protein.  Since the crystal packing is highly affected by the 
surface residues, hardly conserved among the orthologues, screening of different 
orthologues increase the probability of finding good crystals.  The other limitation is 
dealing with small crystals for the difficulty in handling and their susceptibility to 
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radiation damage.  This problem is being addressed by development of microbeam and 
robotics for a better mounting and data collection with the micro crystals. 
Summary of Thesis Work.  In the current study the macromolecular X-ray 
crystallography has been used as the tool for determination of three dimensional 
structures of enzymes involved in thiamin biosynthetic and pyrimidine salvage 
pathways.  The enzymes involved in cofactor biosynthetic pathways have been of 
great interest due to their application as suitable drug targets, the novel chemistry 
involved in the catalytic reactions.  The comparison of biosynthetic pathways existing 
in prokaryotes and eukaryotes also provide with the evolutionary implication.  In 
addition to the biosynthetic pathways there are some energy efficient salvage 
pathways where the preformed nucleotides are metabolized into precursors for the 
synthesis of other nucleotides.  The roles of the purine and pyrimidine nucleotide 
metabolic pathways, in diseases like cancer and viral infection have indicated many of 
the involved enzymes as suitable drug target, hence triggering their structural study. 
Thiamin (Vitamin B1), an essential molecule for all living systems serves as an 
important cofactor for enzymes involved in carbohydrate and amino acid metabolism 
(13).  Bacteria, plant and fungi can synthesize thiamin whereas most other eukaryotes 
rely on nutritional thiamin intake.  Thiamin biosynthesis has been the focus of study 
for several years due to various reasons (14).  The biosynthesis involves some 
unusually unprecedented chemistry hence important from the mechanistic point of 
view.  Morover, the studies on biosynthesis can be used for commercial production of 
thiamin and its components by fermentation.  The biosynthetic process is very well 
characterized in prokaryotes both structurally and mechanistically (Figure 1.1).  On 
the other hand the eukaryotic biosynthetic pathway is still in an emerging state (Figure 
1.2).  
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Figure 1.1.  Thiamin biosynthesis in prokaryotes. 
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Figure 1.2.  Thiamin biosynthesis in eukaryotes.
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In Chapter 2, structural characterization of the bifuctional enzyme THI6, 
involved in thiamin biosynthesis of eukaryotes has been described.  THI6 is a 
bifunctional enzyme found in the thiamin biosynthetic pathway of eukaryotes.  The N-
terminal domain of THI6 catalyses the ligation of the thiamin thiazole and pyrimidine 
moieties to form thiamin phosphate and the C-terminal domain catalyzes the 
phosphorylation of 4-methyl-5-(hydroxyethyl)thiazole in a salvage pathway.  In 
prokaryotes, thiamin phosphate synthase and 4-methyl-5-(hydroxyethyl)thiazole 
kinase are separate gene products.  Here we report the first crystal structure of a 
eukaryotic THI6 along with several complexes that characterize the active sites 
responsible for the two chemical reactions.  THI6 from Candida glabrata is a 
homehexamer in which the six protomers form a cage like structure.  Each protomer is 
composed of two domains, which are structurally homologous to their monofunctional 
bacterial counterparts.  Two loop regions not found in the bacterial enzymes provide 
interactions between the two domains.  The structures of different protein-ligand 
complexes define the thiazole and ATP binding sites of the 4-methyl-5-
(hydroxyethyl)thiazole kinase domain, and the thiazole phosphate and 4-amino-5-
(hydroxymethyl)-2-methylpyrimidine pyrophosphate binding sites of the thiamin 
phosphate synthase domain.  Our structural studies reveal that the active sites of the 
two domains are 40 Å apart and are not connected by an obvious channel.  
Biochemical studies show that both 4-methyl-5-(hydroxyethyl)thiazole phosphate and 
the 2-carboxy-4-methyl-5-(hydroxyethyl)thiazole phosphate are substrates for THI6; 
however, adenosine diphospho-5-(β-ethyl)-4-methyl-thiazole-2-carboxylic acid, the 
product of THI4 is not a substrate for THI6.  This suggests that unidentified enzyme 
may be necessary to produce the substrate for THI6 from the THI4 product. 
 Chapter 3 describes the structural and biochemical characterization of THI1 
from Zea maize, a thiazole synthase involved in eukaryotic thiamin biosynthetic 
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pathway.  The structural work was pursued to investigate the role of the residue 
Val211 in this particular enzyme, as genetic mapping showed that Val211Met 
mutation resulted in a phenotype called Bladekiller 1, in which maize plants develop 
some unusual characteristics, such as poor development of leaf blades, premature 
termination of meristems etc.  The three dimensional structure of the wild-type 
enzyme in a complex form with the product have been described.  Biochemical assays 
reveal that the wild type enzyme purified with the bound metabolites but the mutant 
does not.  The dynamic light scattering studies show that the wild type enzyme forms 
an octamer in solution state unlike the mutant enzyme.  Three additional mutants have 
been designed where the Val211 has been replaced by Ala (small side-chain), Leu 
(medium side-chain) and Phe (large side-chain) residues, to support our hypoyhesis 
that replacement of Val211 by a larger Met residue causes hindrance in thiazole 
biosynthesis and octamer formation.  The crystal structure of V211A shows that the 
octameric state is retained by that mutant whereas some effects of the mutation are 
seen in thiazole biosynthesis. 
Uridine phosphorylase is a crucial enzyme in the pyrimidine salvage pathway, 
which provides an alternative to the de novo biosynthetic pathway.  This enzyme 
catalyzes the reversible phosphorolysis of uridine and 2′-deoxyuridine, as well as their 
analogues to respective nucleobases and ribose 1-phosphate.  This enzyme plays a 
vital role in the homeostatic regulation of both intracellular and plasma uridine 
concentrations.  It has been shown that the toxicity of antitumor (5-fluorouracil) (15) 
and anti-AIDs (3'-azido-3'-deoxythymidine) (16) drugs can be antagonized by 
administration of exogenous uridine.  High doses of uridine are required to produce 
this therapeutic effect due to poor oral bioavailability and short half life of plasma 
uridine (two minutes) (17).  However such large doses of uridine are not well tolerated 
and produce toxic side effects like phlebitis, pyrogenic reactions and diarrhea, 
  9 
resulting form the accumulation of uridine catabolites.  Inhibition of uridine 
phosphorylase activity can maintain an adequate concentration of uridine in the blood 
to alleviate the toxic effects of drugs (18)  This modulation of uridine catabolism by 
inhibitors has been successfully used to attain the effect of substantial doses of uridine 
without the toxic side effects.  The manipulation of uridine pool using uridine 
phosphorylase inhibition is also extended to the treatment of other pathological and 
physiological disorders like CNS disorders, sleep promotion, muscle performance, 
liver disease, cardiac damage and hereditary orotic aceduria.  Hence the structural 
information about mammanlian uridine phosphorylase is immensely important for the 
drug designing viewpoint. 
Chapter 4 describes the trapping of glycal in the active sites of bacterial 
(Escherichia coli) and mammalian (Bos taurus) uridine phosphorylase.  Here we have 
reported the structure of hexameric Escherichia coli uridine phosphorylases treated 
with 5-fluorouridine and sulfate and dimeric bovine uridine phosphorylase treated 
with 5-fluoro-2′-deoxyuridine. In each case the electron density shows three separate 
species corresponding to the pyrimidine base, sulfate and a ribosyl species. NMR time 
course studies demonstrated that uridine phosphorylase can catalyze the hydrolysis of 
these fluorinated nucleosides in the absence of phosphate or sulfate. Crystallization 
with the hydrolysis products in the presence of sulfate is then proposed to result in the 
anti-elimination of water across the C1-C2 bond of UPase-bound ribose. In the 
structures of the glycal complexes the fluorouracil O2 atom is appropriately positioned 
to act as the general base required for this elimination reaction. Crystals of bovine 
uridine phosphorylase treated with 2′-deoxyuridine and sulfate show intact nucleoside. 
This nucleoside is unactivated toward cleavage of the N-ribosyl bond in the absence of 
phosphate.
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 These results add a previously-unencountered mechanistic motif to the body of 
information on glycal formation catalyzed by enzymes which catalyze the cleavage of 
glycosyl bonds. 
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CHAPTER 2 
THE CRYSTAL STRUCTURE OF CANDIDA GLABRATA THI6, A 
BIFUNCTIONAL ENZYME INVOLVED IN THIAMIN BIOSYNTHETIC 
PATHWAY OF EUKARYOTES 
Section 2.1 Introduction 
 Thiamin (vitamin B1) is an essential component of all living systems.  
The active form of thiamin, thiamin pyrophosphate (ThDP), acts as a cofactor for 
several important enzymes in carbohydrate and amino acid metabolism (1).  The 
mechanistic role of the cofactor is stabilization of an acyl carbanion intermediate (2).  
Thiamin biosynthetic pathways are found in prokaryotes and some eukaryotes (yeast, 
fungi and plants); however, vertebrates cannot synthesize thiamin.  Therefore, thiamin 
is an essential component of the human diet with a daily requirement of 1.4 mg.  
Deficiency of thiamin leads to diseases such as beriberi and Wernicke-korsakoff 
syndrome (3).  The absence of thiamin biosynthetic enzymes in mammals makes them 
potential targets for new antimicrobial and antifungal drug design. 
 Thiamin is composed of a thiazole and a pyrimidine moieties, which are 
synthesized separately and joined to form thiamin phosphate (ThMP).  Prokaryotes 
and eukaryotes use different strategies for the production of thiamin.  The detail of 
thiamin biosynthesis is well characterized both structurally and mechanistically in 
prokaryotes (4).  Thiazole formation in bacteria requires six gene products and 
involves the oxidative condensation of 1-deoxy-D-xylulose-5-phosphate, glycine (in 
Bacillus subtilis) or tyrosine (in Escherichia coli) and cysteine (5).  Formation of 4-
amino-5-(hydroxymethyl)-2-methylpyrimidine phosphate (HMP-P) occurs by a 
complex rearrangement of 5-aminoimidazole ribonucleotide catalyzed by ThiC (6), a 
member of the radical SAM superfamily of enzymes.   HMP-P is further 
phosphorylated by the enzyme ThiD to form 4-amino-5-(hydroxymethyl)-2-
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methylpyrimidine pyrophosphate (HMP-PP) (7). The thiazole and pyrimidine modules 
are then coupled by the enzyme thiamine phosphate synthase (TPS) to form ThMP 
(Figure 2.1A) (8), which is finally phosphorylated to ThDP by the enzyme ThiL (9). 
In addition to the biosynthetic pathway, many organisms contain salvage 
pathways.  The enzyme 4-methyl-5-(hydroxyethyl)thiazole kinase (ThiK) catalyzes 
the adenosine 5′-triphosphate (ATP)-dependent phosphorylation of 4-methyl-5-
(hydroxyethyl)thiazole (Thz) to form 4-methyl-5-(hydroxyethyl)thiazole phosphate 
(Thz-P) (Figure 2.1B) (10).  ThiD is responsible for the phosphorylation of 4-amino-5-
(hydroxymethyl)-2-methylpyrimidine (HMP) (7). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.  Chemical reactions catalyzed by CgTHI6.  (A) Reaction catalyzed by the 
N-terminal thiamin phosphate synthase domain.  (B) Reaction catalyzed by the C-
terminal thazole kinase domain. 
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In contrast to the prokaryotic system, the mechanistic and structural 
understanding of thiamin biosynthesis is still at an early stage in the eukaryotes.  
Currently, only three enzymes are known to catalyze the biosynthesis of ThMP.   
THI4 converts nicotinamide adenine dinucleotide, glycine and a yet unknown sulfur 
source to form the adenosine diphospho-5-(β-ethyl)-4-methyl-thiazole-2-carboxylic 
acid (ADT) (11, 12).  THI5 is responsible for HMP-PP formation; however, the 
mechanistic and structural details of this process remain unknown (13).  The coupling 
of CO2-Thz-P and HMP-PP, in eukaryotes, is catalyzed by THI6 (14).  This 
bifunctional enzyme contains a TPS domain and a ThiK domain.  Earlier studies on 
THI6 from Saccharomyces cerevisiae showed that the N-terminal domain is 
responsible for the TPS activity and the C-terminal domain is responsible for ThiK 
activity (15).     
 Here we report the crystal structures of unliganded Candida glabrata THI6 
(CgTHI6) and of several complexes that map out the two active sites.  These include 
ThMP; ThMP and pyrophosphate (PP); Thz and β,γ-methylene adenosine 5′-
diphosphate (AMP-PCP); ThMP and AMP-PCP and 4-amino-5-(hydroxymethyl)-2-
(trifluoromethyl)-pyrimidine pyrophosphate (CF3HMP-PP) and CO2-Thz-P.  The 
THI6 structure reveals a cage-like homohexamer in which the two active sites are 
separated by about 40 Å.  The two active sites are not connected by an obvious 
channel. We also report biochemical studies that show that the TPS domain accepts 
Thz-P as a substrate, but not ADT, the product of THI4. 
Section 2.2 Experimental 
Chemical Reagents.  Kanamycin, ThMP, sodium pyrophosphate, Thz, AMP-
PCP, ATP, magnesium chloride and the buffer components were all purchased from 
Sigma-Aldrich.  Ni-NTA resin was obtained from Qiagen (Valencia, CA).  HPLC 
grade solvents were obtained from Fisher Scientific.  Thz-P and HMP-PP for the 
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activity assays were synthesized by Abhishek Chatterjee as previously described (16).  
The adenylated thiazole (Thz-ADP) was also described by Abhishek Chatterjee, by 
mixing, commercially available adenosine monophosphate morpholidate and Thz-P in 
dry pyridine.  An overnight reaction at room temperature generated Thz-ADP which 
was purified by anion exchange chromatography (17).  TEV protease was provided by 
Cornell Protein Production Facility. 
Expression and Purification of CgTHI6.  The CgTHI6 gene was cloned into a 
modified pET28 overexpression vector encoding an N-terminal hexahistidine tag with 
a TEV protease cleavage site.  The plasmid CgTHI6.XF1 was transformed into 
Escherichia coli cell line BL21(DE3).  A 10 mL overnight culture, grown in Luria-
Bertani media at 37 ºC supplemented with 100 µg/mL ampicillin, was used to start a 1 
L culture.  Growth at 37 ºC was allowed until the OD600 reached 0.5 at which point the 
temperature was reduced to 15 ºC.  After 45 min of cooling the culture was induced 
with 0.1 mM isopropyl-1-β -D thiogalactopyranoside (IPTG) and allowed to grow 
overnight at 15 ºC.  Cells were harvested by centrifugation at 9000 g for 15 min at 4 
ºC using an Avanti J-251 centrifuge (Beckman) and frozen at -20 ºC for later use. 
 The purification was carried out at 4 °C.  The frozen cell pellet was thawed and 
resuspended in 50 mL of lysis buffer [50 mM Tris (pH 8.0), 300 mM NaCl, 10 mM 
imidazole and 3 mM β-mercaptoethanol (BME)] and lysed by sonication.  Cellular 
debris was removed by centrifugation at 35000 g for 50 min at 4 ºC.  The clarified 
lysate was loaded onto a Ni-NTA column (Qiagen) pre-equilibriated with 50 mL of 
the lysis buffer.  The column was then washed with 100 mL of wash buffer [50 mM 
Tris (pH 8.0), 300 mM NaCl, 60 mM imidazole and 3 mM BME] to remove the 
nonspecific binding proteins.  CgTHI6 was eluted with elution buffer [50 mM Tris 
(pH 8.0), 300 mM NaCl, 250 mM imidazole and 3 mM BME].   
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The elution was monitored by measuring protein concentration via Coomassie Plus 
Protein Assay Reagent (Pierce).  
To remove the N-terminal hexahistidine tag, the eluted protein was incubated 
with TEV protease, in dialysis tubing (Pierce) with a 10 kDa molecular weight cutoff 
(MWCO) (Millipore) for 12 h at 4 °C, in a buffer containing, 50 mM Tris (pH 8.0), 
150 mM NaCl, 1 mM DTT.  The proteolysis was monitored by SDS-PAGE analysis.  
After complete proteolysis, the reaction mixture was reloaded onto a Ni-NTA column 
and the flow through was collected.  The non-binding material was buffer exchanged 
into 10 mM Tris (pH 7.5), 50 mM NaCl.  The protein was then concentrated to 8 
mg/mL using a 30 kDa MCWO  Amicon Ultracentrifugal filter (Millipore) and stored 
at -80 °C for future use.  Protein concentration was determined by the Bradford 
method (18) with bovine serum albumin as standard.  The purity of the protein was 
determined by Coomassie-stained SDS-PAGE analysis and was found to be greater 
that 95% (data not shown). 
 Crystallization of CgTHI6 in Unliganded and Complex Forms.  The 
crystallization experiments were conducted at 22  ºC using hanging-drop vapor 
diffusion by combining 1 µL of protein solution and 1 µL of reservoir solution.  Initial 
crystallization conditions of unliganded CgTHI6 were determined using sparse matrix 
screens, Crystal Screen 1 and 2 (Hampton research).  The final optimized condition 
contained 0.1 M HEPES (pH 7.5), 0.2-0.25 M MgCl2 and 25%-32% polyethylene 
glycol400 (PEG400).  Rod shaped crystals, 200-300 µm long, appeared in 2-3 days.   
Crystals of the THI6/ThMP complex were obtained by cocrystallization under 
similar conditions.  The enzyme was incubated with 2.5 mM of ThMP at 4 ºC for 1 h 
prior to crystallization.  The crystals grew after 2-3 days to the maximum size of 400 
µm. 
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Additional complexes were prepared by soaking CgTHI6 crystals with the 
appropriate ligands.  The THI6/ThMP/PP complex was prepared by transferring 
CgTHI6 crystals into a solution containing the mother liquor with 5 mM ThMP and 5 
mM sodium pyrophosphate and soaking for 1 h at 22  ºC.  The THI6/Thz/AMP-PCP 
was obtained by soaking CgTHI6 crystals in a solution containing the mother liquor 
with 20 mM Thz and 20 mM AMP-PCP for 12 h at 22  ºC.  The THI6/ThMP/AMP-
PCP complex was obtained by soaking the CgTHI6 crystals in mother liquor solution 
containing 20 mM each of ThMP, Thz and AMP-PCP for 2 h at 22 ºC.  However Thz 
was not bound in the active site.  The THI6/CF3HMP-PP/CO2-Thz-P complex was 
obtained by soaking CgTHI6 crystals in a solution containing 10 mM each of the 
ligands for 1 h at 22 ºC. 
The high concentration of PEG400 in the mother liquor acted as a cryo-
protectant.  Crystals were flash frozen directly from the drop by plunging them into 
liquid nitrogen. 
Data Collection and Processing.  All data were collected at the NE-CAT 
beamlines 24-ID-E or 24 -ID-C at the Advanced Photon Source at Argonne National 
Laboratory using a Quantum 315 X-ray detector (Area Detector Systems Corporation).  
Crystals of CgTHI6 initially diffracted to ~ 3 Å but were very sensitive to radiation 
damage.  As a result, a highly attenuated beam with 10 sec exposure time, 1º 
oscillation and 400 mm of crystal to detector distance were used to record the 
diffraction images.  To obtain a complete dataset, multiple segments of data were 
collected by exposing the same rod-shaped crystal at different spots and merged 
together. The data were indexed, integrated and scaled using HKL2000 program suite 
(19).  The data collection and processing statistics are shown in Table 2.1. 
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Table 2.1.  Data collection statistics.  Values for the highest resolution shell are given 
in parentheses.  
 
   THI6  THI6/ThMP THI6/ThMP−
PP 
THI6/ThiZOH/
AMP-PCP 
THI6/ThMP/ 
AMP-PCP 
THI6/CF3H
MP-
PP/CO2-
Thz-P 
Wavelength (Å) 0.9795 0.9795 0.9795 0.9795 0.9795 0.9795 
Resolution (Å) 3.2 3.0 3.1 3.3 2.6 3.2 
Space group P21 P21 P21 C2 C2 P21 
Unit Cell       
a (Å) 102.4 104.5 105.2 161.3 163.2 104.9 
b (Å) 153.0 154.3 154.6 153.9 153.5 154.2 
c (Å) 146.7 148.6 148.6 108.6 109.6 148.7 
β (º) 102.3 102.5 102.1 117.6 117.9 102.1 
Matthews 
coefficient 
3.1 3.3 3.4 3.4 3.5 3.2 
% solvent 60.1 63.3 63.7 64.1 64.7 62.3 
mol/asym 6 6 6 3 3 6 
Reflections 75076 273270 188896 163837 143976 159587 
Unique reflections 38571 84611 72303 32447 69157 74009 
Completeness (%) 93.8 (68.9) 93.2 (61.0) 86.6 (71.3) 91.5 (58.7) 96.5 (82.3) 98.5 (95.9) 
Rsym *(%) 10.6 (32.8) 10.3 (26.9) 11.0 (34.8) 14.8 (39.7) 6.3 (35.5) 8.1 (42.6) 
I/σ 13.7 (2.3) 9.5 (1.8) 8.5 (1.4) 7.8 (1.6) 11.6 (1.8) 12.8 (1.9) 
Redundancy 2.1 (2.1) 3.2 (2.1) 2.6 (1.9) 5.0 (2.8) 2.1 (1.9) 2.2 (2.0) 
 
*Rsym = ΣΣi Ii−<Ι>/Σ<Ι>, where <I> is the mean intensity of the N reflections with 
intensities Ii and common indices h,k,l. 
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Structure Determination and Refinement.  Blast searches (20) showed that the 
N-terminal domain of CgTHI6 is about 30% identical to Bacillus subtilis TPS 
(BsTPS) and the C-terminal domain is about 30% identical to Bacillus subtilis ThiK 
(BsThiK).  As a result, molecular replacement was used for the structure 
determination of unliganded CgTHI6.  The Matthews number (21) suggested that the 
asymmetric unit contains six monomers with solvent content of 60.1%.  A homology 
model containing three C-terminal domains of THI6 was generated using trimeric 
BsThiK (PDB entry 1C3Q) as a template.  Only conserved side chains, based on 
sequence alignments of CgTHI6 with multiple bacterial thiazole kinases using 
ClustalW (22), were retained in the homology model.  Molecular replacement using 
CNS (23) revealed the orientations and positions of two trimeric assemblies.  After 
fixing the assemblies from the C-terminal domains, the six N-terminal domains were 
found by molecular replacement using MOLREP (24) with a monomer of BsTPS 
(PDB entry 2TPS) as the search model. 
All model building was performed using the computer program COOT (25).  
The initial refinement was done using CNS and involved successive rounds of rigid 
body refinement, simulated annealing, temperature factor refinement, energy 
minimization and model rebuilding.  Tight non-crystallographic symmetry restraints 
(NCS) were used throughout the refinement.  The sixfold NCS averaged maps were 
generated using the RAVE suit of programs (26).  NCS averaged electron density 
maps and averaged composite omit maps were used for all stages of model building.  
Final rounds of refinements were performed using the PHENIX suit of programs (27) 
with tight NCS restraints. 
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Structure determinations of the CgTHI6-ligand complexes were carried out 
using the unliganded structure as a starting point.  The THI6/Thz/AMP-PCP complex 
crystallized in space group C2 with three CgTHI6 chains per asymmetric unit.  The 
structure was readily determined by molecular replacement using half of a hexamer as 
the search model.  Successive rounds of rigid body refinement, simulated annealing, 
temperature factor refinement and energy minimization were carried out, followed by 
model rebuilding.  After few rounds of refinement the NCS averaged electron density 
map was used to position the ligands in the active site.  PRODRG was used to 
generate the topology and parameter files of ligands, required for refinement (28).  
The final refinement statistics are summarized in Table 2.2.  
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Table 2.2.  Refinement statistics.  
 
 
aR factor = ΣhklFobs - kFcal/ΣhklFobs, where Fobs and Fcal are observed and 
calculated structure factors, respectively.  In bRfree the sum is extended over a subset of 
reflections that were excluded from all stages of refinement.  
 
 
THI6 THI6/ThMP THI6/ThMP/ 
PP 
THI6/Thz/A
MP-PCP 
THI6/ThM
P/ 
AMP-PCP 
THI6/ 
CF3HMP-PP/ 
CO2-Thz-P 
Resolution (Å) 3.2 3.0 3.1 3.3 2.6 3.2 
No of protein atoms 22510 22678 22967 11429 11967 22584 
No of ligand atoms - 144 192 128 162 222 
RMSD 
Bonds (Å) 
Angles (deg) 
 
0.009 
1.165 
 
0.008 
1.012 
 
0.007 
1.115 
 
0.006 
1.084 
 
0.008 
1.120 
 
0.010 
1.227 
 
 
R factor a (%) 21.38 21.25 20.50 20.44 21.23 20.1 
Rfree b (%) 24.48 24.18 25.10 24.29 24.40 23.2 
Ramachandran plot 
Most favored (%) 
Additional allowed (%) 
Generously allowed (%) 
Disallowed (%) 
 
 
86.1 
12.3 
1.6 
0.0 
 
 
88.4 
10.0 
1.4 
0.2 
 
 
 
85.2 
12.8 
1.7 
0.3 
 
81.6 
15.8 
2.3 
0.3 
 
88.0 
11.2 
0.8 
0.0 
 
85.7 
12,2 
1.8 
0.2 
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Biochemical Assay of CgTHI6 Activity. The reaction mixtures of following 
composition were incubated at room temperature for 2 h.  ThiK activity assay: 1.2 mM 
Thz, 2 mM ATP, 2 mM MgSO4 and 33 µM purified enzyme in 50 mM Tris-HCl 
containing 150 mM NaCl and 2 mM dithiothreitol (DTT).  TPS activity assay: 1.2 mM 
Thz, 2 mM ATP, 2 mM MgSO4, 1 mM HMP-PP and 33 µM purified enzyme in 50 
mM Tris-HCl containing 150 mM NaCl and 2 mM DTTs.  ADT cleavage activity 
assay:  100 µm ADT, 2 mM MgSO4 and 33 µM purified enzyme in 50 mM Tris-HCl 
containing 150 mM NaCl and 2 mM DTT.  A reaction in which the enzymes was 
replaced by the reaction buffer served as a control.  
HPLC Analysis of CgTHI6 Catalyzed Reactions.  Analytical HPLC was carried 
out using a Supelco LC-18-T (150x4.6 mm, 3 µm ID) reverse phase column.  HPLC 
analyses were performed in an Agilent 1100 instrument equipped with an inline diode-
array detector.  The enzyme was denatured by heat (100 °C, 40 s) and the reaction 
mixtures were rapidly cooled on ice. The precipitated protein was removed by 
centrifugation and the supernatant was filtered through a 10 kDa MWCO filter 
(Microcon YM-10, Millipore).  100 µL of the filtrate was analyzed by reversed phase 
HPLC.  The following linear gradient was used at 1 mL/min flow rate (solvent A is 
water, solvent B is 100 mM KPi, pH 6.6, solvent C is methanol): 0 min 100% B, 5 min 
10% A 90% B, 8 min 25% A 60% B 15% C, 14 min 25% A 60% B 15% C, 19 min 
30% A 40% B 30% C, 21 min 100% B, 30 min 100% B.  The absorbance at 261 nm 
was monitored.  Different compounds were identified in the chromatogram by 
comigration with authentic standards.  
 Figure Preparation.  All figures were prepared using ClustalW (22), ESPript 
(29) or PYMOL (30). 
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Section 2.3 Results 
Overall Structure of CgTHI6.  The crystal structure shows that the enzyme is a 
hexamer composed of six identical protomers with 32 point symmetry (Figure 2.2A, 
B).  The cage-like hexamer has the shape of a prolate spheroid with a diameter along 
the twofold axis of about 100 Å and a length along the threefold axis of about 150 Å.  
The inner cavity of the cage has a maximum diameter of about 55 Å (Figure 2.3).  The 
presence of the cavity contributes to the high solvent content (~60%) of the crystals, 
and explains previous results from analytical size exclusion chromatography, which 
suggested THI6 was an octamer (14).  The caps of the prolate spheroid are formed by 
trimeric assemblies of the C-terminal (ThiK) domains and the equator is formed by 
dimeric assemblies of the N-terminal (TPS) domains.  The trimeric caps contact each 
other only through the TPS dimers; TPS dimers contact the trimers, but not each other. 
An interesting aspect of the structure of this multidomain protein is the 
formation of the hexameric assembly by combination of the two trimeric C-terminal 
and three dimeric N-terminal domains.  The two trimeric C-terminal domains form the 
top and bottom core of the structure, connected by three dimeric N-terminal subunit 
bridges.  
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Figure 2.2.  (A) Stereo diagram showing cartoon representation of the quaternary 
structure of CgTHI6 hexamer color coded by subunits.  (B) Cartoon representation of 
the quaternary structure of CgTHI6 hexamer color coded by domains; N-terminal 
domains are colored in cyan and C-terminal domains are green.   
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Figure 2.3. Stereo diagram showing the central cavity of CgTHI6, color coded by 
domain.  
CgTHI6 Protomeric Structure.   The protomer consists of two domains (Figure 
2.2B).  The N-terminal domain composed of the residues 1-236 and the C-terminal 
domain composed of residues 248-540.  The domains are connected by a linker, 
consisting of 11 amino acid residues 237-247.  The N-terminal domain has a (βα)8 
barrel fold also known as TIM barrel fold.  The structural fold is characterized by 
eight parallel β strands tilted at an angle of 45º from the barrel axis, surrounded by 
eight α helices.  In addition to those eight α helices, flanking the barrel, there are two 
310 helices.  The first one, α0 forming a cap near the N-terminal end (residues 7-10) 
and the second one, α80 formed by residues 210-213, connecting β8 and α8.  This 
helix is approximately tilted to angle of about 20º to the axis of the TIM barrel helices.  
The β strands are 4-6 residues long, whereas the α helices consist of 4-14 residues, α8 
being the longest one. There are eight loops connecting the alternative helical and 
strand segments.  The active site loop formed by residues 143-153 is disordered in the 
unliganded structure. 
The C-terminal domain has an α/β fold.  The centrally located, nine stranded 
mixed β sheet is flanked by 11 α helices.  The β sheet has a topology: β′2↑ β′1↑ β′3↑ 
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β′4↑ β′5↑ β′6↑ β′7↓ β′8↓ β′9↓.  The helices α′3, α′4, α′5, α′6, and α′7 are packed on 
one side of the sheet being antiparallel to the strands of the sheets.  The remaining six 
α helices form a bundle on the opposite side of the sheet.  The strands contain 4-6 
residues and the helices are made up of 6-14 residues.  The C-terminal domains 
assemble to form a trimer in the top and bottom of the egg shaped structure. 
Domain Interactions: Interface between N-terminal and C-terminal Domains.  
Within the protomer, 2630 Å2 is buried at the interface of the TPS and ThiK domains 
(31).  The interface is formed by several interactions (Figure 2.3, Table 2.3).  The first 
interaction is between residues 193-203, a loop joining α7 and β8 of the TPS domain 
and a portion of the loop containing residues 432-438 of the ThiK domain.   
 
 
 
 
 
Figure 2.4.  Ribbon diagram showing interactions between the two domains within 
CgTHI6 protomer.  The N-terminal domain (residues 1-236) is colored in golden 
yellow, C-terminal (residues 248-540) in green and the linker region (residues 237-
247) in red. 
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Table 2.3.  Hydrogen bonds between the N-terminal and C-terminal domains.
N-terminal domain C-terminal domain H-bonding atoms 
Ser202 Ser432 OγN 
Leu203 Ser434 ON 
Lys200 Ala435 ON 
Tyr234 Gly429 NO 
Arg189 Thr359 NH1O 
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The second interaction occurs between residues 230-236 of the TPS domain and the 
loop, consisting of residues 428-432 from the ThiK domain.  The third interaction is 
between part of α7 (residues 188-190) of the TPS domain and a portion of α′5 
(residues 359-361) from the ThiK domain.  Finally, the loop connecting α′10 and α′11 
(residues 479-486) of the ThiK domain interacts with a portion of the linker (residues 
238-241) between the TPS and ThiK domains.  
Domain Interactions: Interface between N-terminal Domains.  The six TPS 
domains of CgTHI6 have (βα)8 barrel folds and pair up to form three dimers.  The 
individual domains are cis to each other with respect to the barrel axis.  The total 
surface area buried at each dimeric interface is approximately 1500 Å2 (31).  The 
major interactions at dimer interfaces include helices α3 (residue 78-84) and α4 
(residue 98-105).  Helix α3 of one monomer is oriented almost perpendicular to the 
barrel axis of the other monomer, interacting with α3 and α4.  A second interaction 
occurs between 49-52 from one domain and 94-97 from the other.  The interface is 
mostly hydrophobic residues, with only one intermolecular hydrogen (Asp76 of one 
monomer and Arg77 of another). 
Domain Interactions: Interface between C-terminal Domains.  The ThiK 
domains group together to form two trimers, which are twisted by about 20º with 
respect to each other.  The trimers are about 78 Å along the edge and about 45 Å thick.  
The total surface area buried between two ThiK domains is approximately 1600 Å2 
(31) and the interface is formed by thee main interactions.  The first interaction occurs 
between part of α′2 (residues 276-279) from one domain and a portion of α′2 residues 
(273-275) from an adjacent domain. The second interaction occurs between a loop 
region from one domain (residues 297-303) and part of α′5 (347-350) form an 
adjacent domain.  The side chain of Glu298 forms hydrogen bonds with the side 
chains of Thr348 and Arg350.  The third interaction occurs between part of helix α′10 
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(residues 515-523) and the loop between α′9 and α′10 (residues 507-513). 
Active Site of the TPS Domain.  The active site of the TPS (N-terminal) domain 
is located in a cavity surrounded by loops 2 (residues 45-51), 4 (residues 92-97) and 6 
(residues 138-154) the (βα)8 barrel.  Loop 6 is the longest one and is partly disordered 
in the unliganded CgTHI6 structure. 
The binding geometry of ThMP in the CgTHI6/ThMP complex is similar to 
that of the BsTPS structure (8).  The main interactions between the protein and the 
ligand are shown in Figure 2.5A.  The V-shaped conformation of ThMP results in part 
from interactions between by Ile79 and both the pyrimidine and thiazole rings.  The 
pyrimidine moiety is buried in a mostly hydrophobic pocket formed by Tyr13, Val15, 
His90, Tyr134, Ile179 and Cys207 and located near the entrance of the barrel.  The 
only hydrogen bond occurs between N3 of the pyrimidine and the side chain of Gln43.  
Other interactions include stacking with His90, Tyr13 and Tyr134.  The thiazolium 
moiety binds in an extended conformation lying under loop 6.  The side chain of 
Lys146, running parallel to the ethyl group of the thiazolium ring provides van der 
Waals interactions.  The phosphate group forms an extensive network of hydrogen 
bonds with Thr143, Thr145, Gly181, Val 209 and Ser210; these residues come mostly 
from loop 6 and α8. 
The pyrophosphate binding site in the CgTHI6/ThMP/PP complex is located 
near the opening of the active site and is more solvent exposed then the ThMP (Figure 
2.5A). The pyrophosphate and the thiazole moiety are present on the opposite faces of 
the pyrimidine ring of ThMP.  Interactions of ThMP are similar to those for the 
CgTHI6/ThMP complex.  Pyrophosphate is stabilized by hydrogen bonds and 
electrostatic interactions.  The electrostatic interactions involve, side-chains of Arg45 
and Lys47 from loop 1, Lys146 from loop 6 and one Mg2+ ion.   
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Figure 2.5.  The active sites of CgTHI6.  (A) Stereo-diagram showing active site of the 
N-terminal domain of the enzyme.  The product ThMP, pyrophosphate and the active 
site residues are shown in ball and stick presentation with carbon atoms in cyan for 
ligand, green for protein, nitrogen in blue, oxygen in red, sulfur yellow and 
phosphorus in orange.  Mg2+ is marked by a magenta sphere.  (B) Stereo-diagram 
showing the carboxy-thiazole binding in the active site of the N-terminal domain of 
the enzyme.  The substrates, CO2-Thz-P, CF3HMP-PP, pyrophosphate and the active 
site residues are shown in ball and stick presentation with carbon atoms in cyan for 
ligand, green for protein, nitrogen in blue, oxygen in red, sulfur yellow and 
phosphorus in orange.  Mg2+ is marked by a magenta sphere.   (C) Stereo-diagram 
showing active site of the C-terminal domain of the enzyme.  The substrate Thz, 
AMP-PCP and the active site residues are shown in ball and stick presentation with 
carbon atoms in cyan for ligand, green for protein, nitrogen in blue, oxygen in red, 
sulfur yellow and phosphorus in orange.  Mg2+ is marked by a magenta sphere. 
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The hydrogen bonding interactions occur between the pyrophosphate oxygen atoms 
and side-chains of Asn75, Asp76, Asp95 and Ser214.  Loop 6 is partly disordered in 
the THI6/ThMP structure (residues 146-149 absent) and becomes ordered after 
pyrophosphate binding.  
In the CgTHI6/ThMP/PP complex structure the Mg2+ is bound on the edge of 
the active site.  The Mg2+ is octahedrally coordinated by the side-chains of Asp76 and 
Asp95 and the oxygen atoms of pyrophosphate.  However in absence of 
pyrophosphate, the Mg2+ binding site is slightly shifted and the ion is tetrahedrally 
coordinated by side-chains of Asp76 and Asp95 and the main-chain of Ala49 and side-
chain of Thr51 from the neighboring monomer. 
CO2-Thz-P is a product of the ThiK reaction and a substrate of the TPS 
reaction; however, in the CgTHI6/CF3HMP-PP/CO2-Thz-P complex (Figure 2.5B), 
density for CO2-Thz-P was found only in the TPS active site.  Similar interactions are 
observed between the thiazole moiety and the protein as for the product analogue 
complexes, CgTHI6/ThMP and CgTHI6/ThMP/PP.  Two lysine residues are 
positioned near the 2-carboxy group of the thiazole ring; Lys146 and Lys151, both of 
them coming from loop 6.  The interactions with the pyrimidine moiety and the 
pyrophosphate remain the same as observed in the other structures. 
Active Site of the ThiK Binding Site.  The Thz binding site in the 
CgTHI6/Thz/AMP-PCP is located at the interface of two domains and is rich in 
hydrophobic residues (Figure 2.5C).  The overall active site is similar to that of 
BsThiK (32).  The main interactions occur from Asn272, Val274 and Thr462 from one 
chain and Ala280, Leu284, Pro290 and Met292 from the other chain.  The only 
hydrogen bond is formed between the nitrogen atom of thiazole ring and the amide 
nitrogen of Met292.  One side of the thiazole ring is stacked against the side chain of 
Val274, while the other side is more solvent exposed.   
  35 
The side chain of Cys467 is positioned near the hydroxyl group of thiazole. 
The ATP binding site is characterized by the two complexes containing the 
nohydrolizable ATP analogue, AMP-PCP.  The site is located near the C-terminal end 
of the central β-sheet and includes β′5, β′6, β′7 and β′8 (Figure 2.5C).  The adenine 
moiety of the nucleotide is positioned under two loops, one containing a β-turn 
connecting β′6 and β′7 (residues 417-419), and the other containing a loop preceding 
α′8 (residues 451-457).  The region containing residues 456-465 becomes ordered 
upon AMP-PCP binding.  The N1 and N3 atoms of the adenine form hydrogen bonds 
with the Ile455 amide nitrogen and the Lys497 side chain, respectively.  The ribose 
moiety is hydrogen bonded with the side chain of Asp420.  One oxygen atom of the α-
phosphate interacts with the hydroxyl group of Thr416.  The side-chain of Lys367 
forms a hydrogen bond with the β-phosphate, which is connected to Mg2+.  The γ-
phosphate of the nucleotide is oriented towards the hydroxyl group of thiazole and is 
hydrogen bonded with the side chain of Cys467 and is coordinated with Mg2+.  A 
second Mg2+ interacts with the β and γ-phosphates of the nucleotide and the side-
chains of the strictly conserved residues Asp340 and Glu372.  
Biochemical Activities of CgTHI6.  Recombinant CgTHI6 exhibited both ThiK 
and TPS activities (Figure 2.6A, B).  When the purified protein was incubated with 
Thz and ATP, formation of Thz-P was noted.  Incorporation of HMP-PP in the same 
reaction resulted in the production of ThMP.  Consumption of Thz in the latter 
reaction was higher, presumably due to the removal of the Thz-P, product of the ThiK 
reaction.  However, incubation of the enzyme with THI4 product ADT did not show 
any reaction suggesting that ADT is not a substrate for THI6 (Figure 2.6C). 
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Figure 2.6.  Activity assays for CgTHI6.  (A) HPLC analyses of the TPS and ThiK 
activities, absorbance measured at 261 nm.  The red trace shows the control where the 
enzyme is not added.  The black trace shows the Thz-P formation in presence of the 
enzyme showing the ThiK activity.  The blue trace shows the ThMP formation in 
presence of the enzyme showing the TPS activity.  (B) HPLC analyses of the TPS and 
ThiK activities, absorbance measured at 261 nm.  The red trace shows the control 
where the enzyme is not added.  The black trace shows the Thz-P formation in 
presence of the enzyme showing the ThiK activity.  The blue trace shows the ThMP 
formation in presence of the enzyme showing the TPS activity.  (C) HPLC analysis of 
ADT cleavage activity, absorbance measured at 261 nm.  The red trace shows the 
control where the enzyme is not added.  The black trace shows that there is no reaction 
in presence of the enzyme.      
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Section 2.4 Discussion 
Reliability of the Medium Resolution Structure.  The resolutions of the reported 
unliganded and complex structures range from 2.6 Å to 3.3 Å, a range considered to 
be medium resolution in protein crystallography.  However, the current structures 
represent a favorable scenario.  The determination of these structures involved 
molecular replacement using high-resolution BsThiK (1.5 Å) and BsTPS (1.25 Å) 
structures as starting models making the current structures were very reliable.  
Furthermore, the presence of six monomers in the asymmetric unit allowed the use of 
a six-fold NCS averaged map for model building and tight NCS restraint for 
refinement, which further strengthened the reliability of the structural information and 
resulted in a small difference between R and R-free (3-4 %).  
Role of Evolution in the Formation of Bifunctional Enzyme. While the 
architecture of this multidomain enzyme and the chemical reactions catalyzed by each 
domain have been unraveled, question still remains regarding a possible cooperative 
interaction between the two domains.  The fusion of a biosynthetic enzyme and a 
salvage enzyme by Nature raises the important question of the role of evolution 
therein.  The fact that the product of the C-terminal domain, Thz-P is a substrate for 
the N-terminal domain explains the rationale behind the formation.  In the current 
structural studies, no evidence is observed for the existence of a channel for the direct 
transfer of Thz-P from one domain to the other. However, the fusion of the two 
domains could be beneficial simply due to the enhancement in the local concentration 
of Thz-P.  The conservation of the oligomeric states in the bacterial monofunctional 
and eukarotic bifunctional enzymes further strengthens the role of evolution in 
structure-function relationship.  
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Figure 2.7.  Comparison between the bifunctional CgTHI6 and its monofunctional 
bacterial homologues.  (A) Ribbon diagram of the N-terminal domain of CgTHI6 
superimposed on BsTPS monomer.  CgTHI6 is colored in cyan and BsTPS in blue.  
(B) Ribbon diagram of the C-terminal domain of CgTHI6 superimposed on BsThiK 
monomer.  CgTHI6 is colored in cyan and BsTPS in blue. 
Structural Comparison with Bacterial TPS.  TPS catalyzes the formation of 
ThMP from HMP-PP and Thz-P.  High resolution structures of this enzyme have been 
reported in unliganded and complex forms from B. subtilis (33) and P. furiosus (PDB 
1XI3).  An initial structural homology search using the DALI server (34) indicated 
that BsTPS is structurally homologous to CgTHI6 having a Z score of 26.5 and 
RMSD 1.9 Å, based on alignment of 236 residues of the N-terminal domain of 
CgTHI6. 
Although the N-terminal domain of CgTHI6 utilizes the same (βα)8 barrel fold 
as BsTPS  (Figure 2.7A), a detailed structural comparison suggests that there are 
certain structural changes between the eukaryotic enzyme and its bacterial homologue.  
The significant differences occur mainly in the loop regions.  The most interesting one 
is the presence of long loop (193-203) in the bifunctional enzyme holding the two 
domains together.  
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The active site residues of the two enzymes are mostly conserved with the 
same binding conformation of ThMP, PP and Mg2+.  A comparison of the active site 
residues has been listed in Table 2.4.  
 
Table 2.4. Comparison of the active site residues of BsTPS and CgTHI6.  
BsTPS CgTHI6 
Gln 57 Gln 43 
Thr 156 Thr 143 
Thr 158 Thr 145 
Gly 168 Gly 181 
Ser 209 Ser 210 
 
 
 
ThMP binding residues 
Ile 208 Val 209 
 
Ser 130 Ser 114 
Arg 59 Arg 45 
Lys 159 Lys 146 
Asn 92 Asn 75 
Pyrophosphate binding residues  
Lys 61 Lys 47 
 
Asp 93 Asp 76 Mg2+ binding residues 
Asp 112 Asp 95 
 
Comparison of the Dimer Interfaces of CgTHI6 with Bacterial TPS and TenI.  
The N-terminal domain of CgTHI6 and BsTPS both exist as dimers of (βα)8 barrels.  
However in the first one the barrel axes are cis to each other unlike in BsTPS, where, 
they are in trans orientation with respect to each other (Figure 2.8).  In BsTPS dimer 
the major interactions occur between two symmetry related α3 helices running parallel 
to each other.  Interestingly the dimeric interface of the bifunctional enzyme is similar 
to PfTPS, the available structure of archaebacterial TPS.  The CgTHI6 dimer is also 
similar to BsTenI (35), which is an enzyme in bacterial thiamin biosynthetic pathway, 
showing a significant structural homology to TPS.  Previous gene identification 
studies have suggested that tenI genes are paralogues of thiE, the gene encoding TPS 
(36).  All three dimers have the barrel axes cis to each other (Figure 2.8).  The 
formation of a different dimeric subunit in BsTPS is not yet well understood.  One 
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possible reason can be considered as an artifact of the crystal packing.  The occurrence 
of same dimeric subunit in PfTPS (archebacterium), BsTenI (eubacterium) and 
CgTHI6 (eukaryote) also suggests the possibility of a divergent evolution, all three 
enzymes originating from a common ancestor.     
 
 
 
 
 
 
 
 
Figure 2.8.  Comparison of the dimeric subunit of CgTHI6 with other enzymes.  (A) 
Ribbon diagram showing dimer of N-terminal domain of CgTHI6.  (B) Ribbon 
diagram showing dimer of BsTPS.  (C) Ribbon diagram showing dimer of BsTenI.  
(D) Ribbon diagram showing dimer of PfTPS.  In all figures the monomers are labeled 
by different colors. 
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Conformational Change upon Ligand Binding in TPS Domain.  A comparison 
between the structures of the unliganded enzyme and the THI6/ThMP and 
THI6/ThMP/PP complexes suggests that there are some conformational changes upon 
ligand binding.  The active site C loop composed of residues 143-153 becomes 
ordered upon product binding.  The residues from the C loop, Thr143 and Thr145 
takes part in phosphate binding of the product ThMP.  The side-chain of Lys146 is 
involved in pyrophosphate binding.  This longest loop acts as a gate near the active 
site, which closes upon the product binding and opens when the reaction is complete 
and the product is dissociated from the enzyme surface.  The other active site loops A 
and B also show some minor changes upon product binding.  
Structural Comparison with Bacterial Thiazole Kinase.  ThiK catalyzes the 
conversion of Thz to  Thz-P, in presence of ATP and Mg2+.  This is a salvage enzyme 
that provides an alternative to the regular thiazole biosynthetic pathway and enables 
the cell to use the recycled Thz.  The crystal structures of the unliganded ThiK, 
ThiK/Thz and ThiK/ThiZP/ATP complexes have been reported from B.  sublitis, in 
monoclinic and rhombohedral forms (32).  Structural similarity between these two 
enzymes was found using DALI search, which showed a Z score of 31.6 and RMSD 
1.9 Å, for 270 superimposed Cα atoms.  The trimeric assembly remains conserved in 
the eukaryotic homologue.   
 The overall fold of C-terminal domain of CgTHI6 is similar to BsThiK, having 
a centrally located β sheet flanked by several α helices on both sides.  The secondary 
structural elements are mostly conserved between the two enzymes (Figure 2.7B).  
The major structural differences are observed in the loop regions.  The presence of the 
insertion (residues 426-446) in the bifunctional enzyme is in the form of a single turn 
helix, α′80 (426-429) followed by an extended loop, interacting with the N-terminal 
domain.  The loop connecting α′9 and α′10 is longer in bifunctional enzyme (residues 
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479-486) and interacts with a portion of the linker between the two domains (residues 
238-241).  The C-terminal helix α′12 composed of residues 256-264 in BsThiK is 
substituted by a single turn helix containing residues 530-533 in CgTHI6.  A very 
interesting observation is that the loop containing residues 379-393 is disordered in 
our current structures.  The corresponding loop containing residues 135-150 is present 
in the ThiK/Thz (rhombohedral crystal form) structure but disordered in ThiK/Thz-
P/ATP complex structure (monoclinic crystal form) (32).  However the structural 
significance of this loop is still not known.  
A comparison of the active site residues between the two enzymes is shown in 
Table 2.5. The active sites are mostly conserved with similar binding orientations of 
Thz, AMP-PCP and Mg2+.   However, there are some minor modifications observed in 
the eukaryotic enzyme.  The thiazole-binding loop containing residues 314-316 is 
slightly shifted away from the ligand in CgTHI6 compaired to the loop containing  
 
 
Table 2.5. Comparison of the active site residues of BsThiK and CgTHI6.  
BsThiK CgTHI6 
Asp 94 Asp 340 
Glu 126 Glu 372 
 
Arg 121 Lys 497 
Asn 123 Asn 369 
Thr 168 Thr 416 
Gly 169 Gly 417 
Glu 170 Glu 418 
Thr 191 Gly 459 
Gly 195 Ala 463 
Ala 196 Ser 464 
Tyr 225 Tyr 496 
Asp 172 Asp 420 
 
Cys 198 Cys 466 
 
Mg2+ Binding residues 
 
 
 
 
AMP-PCP binding residues 
 
 
 
 
 
 
 
 
Thiazole binding residues 
*Met 45 *Met 292 
*Residues from the other chain. 
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residues 66-69 in BsThiK.  The ATP binding site also shows some differences in the 
eukaryotic enzyme.  A very interesting shift of ~8 Å is observed in the ATP binding 
loop containing residues 451-455, compared to the loop containing residues 184-188 
in BsThiK.  The adenine base remains more solvent exposed in the bacterial enzyme 
with no hydrogen bond between the adenine base and the protein.  In the bifunctional 
enzyme the adenine ring is shielded by the loop 451-455.  There are two hydrogen 
bonds between the ring and the protein.  The N1 of the adenine base makes one 
hydrogen bond with the main chain nitrogen of Ile455 and the other one is between N3 
of the adenine base and the side-chain of Lys497, which is replaced by Gly226 in 
BsThiK. 
Conformational Changes Upon Thz and AMP-PCP Binding.  Thz binding in 
the C-terminal domain induces an interesting change of space group from primitive 
monoclinic P21 to C-centered monoclinic C2, having three monomers in the 
asymmetric unit, composing half of the hexamer.  However the whole hexamer is 
generated by the crystallographic 2-fold axis.  The active site loop, preceeded by the 
single turn helix contaning residues 456-464 also becomes ordered upon ligand 
binding.  This observation is consistent with the fact that several residues in this region 
make contact with the ligand.  
Catalytic Mechanism.  The study of the THI6/ThMP and THI6/ThMP/PP 
complexes show that all the active site residues are conserved between CgTHI6 and 
BsTPS.  The binding conformations of the products, ThMP, PP and Mg2+ also remain 
same in the two active sites, indicating the involvement of a similar dissociative 
mechanism with the formation of pyrimidine carbocation (33).  The binding of HMP-
PP and Thz-P to the active site is followed by the closing of the C-loop, forming a 
stable enzyme-substrate ternary complex.  The ionizaton of HMP-PP is facilitated by 
the stabilization of pyrophosphate as a leaving group and the delocalization of the 
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positive charge in the pyrimidine ring.  This intermediate is trapped by the 
nucleophilic thiazole moiety to form thiamin phosphate, followed by the 
decarboxylation.  The decarboxylation is facilitated by the positive charge on nitrogen 
of the thiazole ring.    
The structural comparison of THI6/Thz-P/AMP-PCP complex and ThiK/Thz-
P−/AMP-PCP complex shows that the active site residues are mostly conserved 
between the two enzymes with a similar kind of ligand binding.  This provides an 
insight to the similar mechanism of action between the two enzymes.  The positioning 
of the γ-phosphate of AMP-PCP and the Thz indicates an inline phosphate transfer.  
Cys467 is the probable candidate acting as a nucleophile to deprotonate the thiazole 
alcohol resulting in the phosphorylation.  Interestingly this cystine residue is replaced 
by aspartate in the other known small molecule kinases, ribokinase and adenosine 
kinase (37, 38). 
 The substrates for bacterial TPS are CO2-Thz-P and HMP-PP.  Mechanism of 
the decarboxylation is not yet established in the prokaryotic system.  Recent findings 
indicate that a carboxylated thiazole could be the substrate for thiamin phosphate 
synthase in the eukaryotic system as well.  The active site of THI6/CF3HMP-PP/ CO2-
Thz-P complex shows that CO2-Thz-P binds in the TPS domain, indicating that the 
decarboxylation occurs in the TPS domain of the multidomain enzyme.  There are two 
lysine residue positioned near the carboxylate group, Lys151 and Lys146, at distances 
3.6 Å and 4 Å respectively.  Lys146 running parallel to the ethyl group of the 
thiazolium ring is strictly conserved in the THI6 orthologues as well as the bacterial 
TPS homologues.  On the other hand Lys151 does not remain conserved in the 
eukaryotes and is replaced by a histidine residue (His132) in BsTPS.  Based on this 
conservation among all TPS enzymes, we suggest that Lys146 is likely to be involved 
in binding the negatively charged carboxylate. 
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Absence of ADT Cleavage Activity.  The results from the activity assay clearly 
suggest that ADT, the THI4 product is not a substrate for THI6.  This observation 
raises important questions about how the cleavage of the adenylyl group from ADT 
results in the formation of CO2-Thz-P, a substrate for THI6.  This suggests the 
probability of existence of another enzyme in the biosynthetic pathway. 
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CHAPTER 3 
STRUCTURAL STUDIES ON ZEA MAIZE THIAZOLE 
SYNTHASE: ROLE OF VAL211 
Section 3.1 Introduction 
 Thiamin (vitamin B1) consisting of a thiazole moiety linked to a pyrimidine 
ring, is an essential molecule in all forms of life.  The active form, thiamin 
pyrophosphate (TPP) plays an important role as a cofactor for several enzymes 
involved in carbohydrate and amino acid metabolism (1).  Some important new 
functions of the phosphate esters of thiamin have been recently suggested.  The 
binding of thiamin monophosphate (ThMP) to mRNA domains called “riboswitches” 
regulate the expression of thiamin biosynthetic genes at the transcriptional level (2). 
Recent findings have shown that ThMP also plays a major role in repairing DNA 
damage and increasing mitochondrial stability (3, 4).  Thiamin triphosphate has been 
suggested to play a role in physiology of the nervous system (5).  
Thiamin is biosynthesized by prokaryotes and some eukaryotes, including 
fungi and plants.  Vertebrates including human, need to obtain this essential cofactor 
through diet and deficiency can lead to a disease called beriberi characterized by 
disturbances of the central nervous system (6).  In plants, several mutants defective in 
different stages of thiamin biosynthesis have been reported.  Recent studies on Zea 
maize showed that a mutation in the thiazole biosynthetic gene thi1_2 results a 
phenotype called Bladekiller1 (blk1) exhibiting premature termination of 
influorescence and axillary meristems and poor development of leaf blades (John 
Woodward, private communication).  The point mutation occurs in a highly conserved 
valine residue and replaces it with methionine.  This is caused by a G to A nucleotide 
mutation, common in plants that have been treated with ethylmethylsulfonate.  Two 
isoforms of Zea maize thi1 (thi1_1 and thi1_2) have been functionally assigned as 
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thiazole synthase based on their high sequence similarity with previously 
characterized THI4 from Saccaromyces cerevisiae (ScTHI4) (7).  The isoforms are 
90% identical with tight conservation of the putative active site residues.   
   Thiamin biosynthesis has been studied extensively in prokaryotic systems 
both structurally and mechanistically.  4-methyl-5-(hydroxyethyl)thiazole phosphate 
(Thz-P) and 4-amino-5-(hydroxymethyl)-2-methylpyrimidine pyrophosphate (HMP-
PP) are synthesized through separate routes and then coupled together to form ThMP.  
A final phosphorylation of ThMP leads to the formation of the biologically active 
cofactor. The prokaryotic thiazole biosynthetic pathway involves a complex oxidative 
condensation (Figure 3.1).  In the first step, glyceraldehyde-3-phosphate and pyruvate 
are ligated by the enzyme 1-deoxy-D-xylulose-5-phosphate synthase (DXS) to form 1-
deoxy-D-xylulose-5-phosphate (DXP) (8).  In the following step, the sulfur carrier 
protein ThiS is adenylated by ThiF, followed by a sulfur transfer by ThiI and IscS (E. 
coli) or NifS (B. subtilis) to form a thiocarboxylated C-terminus (9).  Glycine is 
oxidized in B. subtilis by ThiO (10) or tyrosine in E. coli by ThiH (11) to give 
dehydroglycine.  Dehydroglycine is then coupled with DXP and the thiocarboxylated 
ThiS, by thiazole synthase ThiG to form thiazole phosphate carboxylate tautomer (12).  
The thiazole tautomer is then aromatized by TenI (B. subtilis) to form the thiazole 
phosphate carboxylate (CO2-Thz-P) (13).  
 The biosynthesis of thiamin in eukaryotes involves a completely different 
biochemical pathway and has only beginning to emerge.  A single enzyme, known as 
THI4 (in fungi) and THI1 (in plants) catalyzes the thiazole biosynthetic pathway in 
eukaryotes (14).  Nicotinamide adenine dinucleotide (NAD), glycine and a yet 
unknown sulfur source are assembled together to form the final product adenosine 
diphospho-5-(β-ethyl)-4-methyl-thiazole-2-carboxylic acid (ADT) in a complicated 
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Figure 3.1.  Thiazole biosynthesis in prokaryotes. 
biochemical pathway (15).  The trapping and characterization of three adenylated 
metabolites (A, B and C in Figure 4.2) bound to the enzyme, at different stages of the 
pathway, have provided a mechanistic profile for thiazole formation in yeast (15). 
 THI4 is dual functional enzyme also involved in mitochondrial DNA repair 
(3).  The previously determined crystal structures of ScTHI4 and Arabidopsis thaliana 
THI1 (AtTHI1) show that this enzyme exists as a homooctamer (16, 17).  In both the 
structures the product ADT is bound in the enzyme active site.  The structure of 
ScTHI4 shows a cis-proline residue (121), hydrogen bonded to the phosphate group of 
the ADT moiety, suggesting that isomerization of the proline might lead to product 
release.   
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The enzyme from Neurospora crassa is highly expressed (1.5% of the entire 
proteome) and interacts with a cis-trans prolyl isomerase, further supporting this 
hypothesis (18). 
 
 
Figure 3.2.  Thiazole biosynthesis in eukaryotes. 
 Here we report the crystal structure of wild type Zea maize THI1_2 (ZmTHI1) with 
the product ADT bound in the active site at 2.5 Å.  Biochemical studies show that the 
wild-type enzyme purifies with the adenylated metabolites (A, B and C, Scheme 2) but 
the mutant does not.  An assay demonstrating the reconstitution of activity has been 
performed with the wild type enzyme in presence of NAD, glycine and Fe2+.  
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However, such reconstitution failed in case of the mutant.  Dynamic light scattering 
(DLS) has been used to characterize the octameric state of the wild type enzyme in the 
solution state.  Furthermore different mutants have been designed and studied in order 
to investigate the role of Val211 in structural and functional aspects of ZmTHI1.  
   Section 3.2 Experimental 
Chemical Reagents. M9 minimal medium, L-amino acids, magnesium sulfate, 
calcium chloride, Kanamycin, calcium acetate, isopropyl alcohol and the buffer 
components were all purchased from Sigma-Aldrich.  Ni-NTA resin was obtained 
from Qiagen (Valencia, CA).  HPLC grade solvents were obtained from Fisher 
Scientific. 
    Genetic Mapping of blk1.  An F2 mapping population was generated by 
crossing thi1_2-blk1 heterozygotes introgressed into B73 nine times onto the MO17 
inbred.  Known SSR and INDEL markers for 3L were available at maizegdb.org and 
used to delimit the mapping interval. Sequence available at maizesequence.org and 
magi.plantgenomics.iastate.edu/ were used identify candidate genes and build primers 
for amplifying genomic regions.  Sequence polymorphisms between MO17 and the 
thi1_2-blk1 progenitor were used to design CAPS markers that further narrowed the 
mapping interval.  thi1_2 (GRMZM2G074097) was amplified by PCR using primers 
thi2-cDNA-f1 and thi2-cDNA-R1, which flank the predicted coding region.  This 
work was done by John Woodward in Prof. Michael Scanlon’s laboratory. 
Cloning of ZmTHI1 and its Mutants.  The ZmTHI1 clones were prepared by 
Cornell Protein Facility, using standard method of DNA manipulation (19, 20).  
Plasmid DNA was purified using the Qiagen Miniprep kit.  E. scoli strain MachI 
(Invitrogen) was used for transformations during plasmid construction, propagation 
and storage.  The first 47 N-terminal residues were chopped off because they encoded 
signaling sequence.  Site-directed mutagenesis was performed by a standard PCR 
  57 
protocol uring Pfu Turbo DNA polymerase per the manufacturer'e instructions 
(Invitrogen).  The primers used for all constructs are listed in Supplemental Table 1.     
Expression and Purification of ZmTHI1 and its Mutants.  The wild-type and 
mutant ZmTHI1 genes were cloned into a modified pET28 overexpression vector 
encoding an N-terminal hexahistidine tag with a TEV protease cleavage site.  The 
plasmid was transformed into Escherichia coli (Novagen) cell line BL21(DE3).  A 
single colony was used to inoculate a 10 mL overnight culture, grown in Luria-Bertani 
media at 37 ºC supplemented with 60 µg/mL kanamycin.  The saturated starter culture 
was then added to 1L of LB media, containing the same antibiotics and grown at 37 ºC 
with shaking at 200 rpm until the OD600 reached 0.7.   At this point the culture was 
cooled to 15 ºC for 45 mins and induced with 0.1 mM isopropyl-1-β -D 
thiogalactopyranoside (IPTG) for 16 – 18 h.  Cells were harvested by centrifugation at 
9000 g for 15 min at 4 ºC using an Avanti J-251 centrifuge (Beckman) and frozen at -
20 ºC for later use. 
 All purification steps were carried out at 4 °C.  The frozen cell pellet from 2L 
ofculture was thawed and resuspended in 50 mL of lysis buffer [50 mM Tris (pH 8.0), 
300 mM NaCl, 10 mM imidazole] with the addition of Protease Inhibitors (Roche) and 
lysozyme (1 mg/mL).   The cells were lysed by sonication in an ice-water bath.  A 
Sonic Dismembrator 500 from Fischer Scientific was used with a 5 s pulse followed 
by 10 s of cooling over a period of 1 minute and repeated twice .   Cellular debris was 
removed by centrifugation at 35000 g for 50 min.  The clarified lysate was then loaded 
onto a 2 mL Ni-NTA column (Qiagen) pre-equilibriated with 50 mL of the lysis 
buffer.  The column was then washed with 100 mL of wash buffer [50 mM Tris (pH 
8.0), 300 mM NaCl, 60 mM imidazole] to remove any nonspecific binding 
contaminants.  ZmTHI1 was eluted with elution buffer [50 mM Tris (pH 8.0), 300 
mM NaCl, 250 mM imidazole].  The elution was monitored by measuring protein 
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concentration via Coomassie Plus Protein Assay Reagent (Pierce).  The proteins were 
further purified by gel filtration chromatography.  A Hi-Load Superdex 200 column 
(26/60, GE Healthsciences) was equilibrated with 50 mM Tris buffer (pH 8.0) and 100 
mM NaCl.  Pure protein was eluted at a flow rate of 1 mL/min while monitoring the 
A280 nm and collecting 2 mL fractions.  The fractions containing the protein as 
evidenced by SDS-PAGE gel analysis were combined and concentrated to 10 mg/mL 
using an Amicon Ultra centrifugal device with a 10 kDa MWCO (Millipore).  The 
purity of the proteins was found to be greater than 95 %  assessed by Coomassie-
stained SDS-PAGE analysis (data not shown). 
 Crystallization of ZmTHI1.  The crystallization experiments were conducted at 
22 ºC using hanging-drop vapor diffusion by combining 1 µL of wild type ZmTHI1 
solution and 1 µL of reservoir solution.  Initial crystallization conditions were 
determined using sparse matrix screens, Crystal Screen 1 and 2 (Hampton research).  
The final optimized condition contained 0.1 M MES (pH 6-6.3), 0.2-0.25 M calcium 
acetate and 10%-12% isopropyl alcohol.  Diamond shaped crystals, 200-300 µm long, 
appeared in 6-8 days.  10% glycerol added to the mother liquor was used as a 
cryoprotectant.  
 The V211A mutant was crystallized under similar condition (0.1 M MES, pH 
6.1, 0.2 M calcium acetate, 12% isopropyl alcohol).  The crystals grew to the size of 
400 µm in 3-5 days.  12% glycerol was used as cryprotectant.  
 Data Collection and Processing.  All data were collected at the NE-CAT 
beamlines 24-ID-E or 24 -ID-C at the Advanced Photon Source at Argonne National 
Laboratory using a Quantum315 X-ray detector (Area Detector Systems Corporation).  
A beam with 1 sec exposure time, 1º oscillation and 400 mm of crystal to detector 
distance were used to record the diffraction images.  The data were indexed, integrated 
and scaled using HKL2000 program suite (21) (Table 3.1).  
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Table 3.1.  Data collection statistics.  Values for the highest resolution shell are    
given in parentheses.  
 
 Wild type 
ZmTHI1 
V211A 
ZmTHI1 
Wavelength (Å) 0.9795 0.9795 
Resolution (Å) 2.5 2.04 
Space group I4 I4 
Unit Cell   
a (Å) 95.9 96.0 
c (Å) 130.9 131.2 
Matthews 
coefficient 
2.3 2.3 
% solvent 47 47 
mol/asym 2 2 
Reflections 69378 158059 
Unique reflections 19530 35797 
Completeness (%) 98.8 (90.5) 95.2 (98.5) 
Rsym *(%) 12.5 (31.4) 7.5 (36.5) 
I/σ 11.4 (2.9) 18.4 (5.0) 
Redundancy 3.1 (2.8) 4.4 (4.1) 
 
*Rsym = ΣΣi Ii−<Ι>/Σ<Ι>, where <I> is the mean intensity of the N reflections with 
intensities Ii and common indices h,k,l. 
 
60 
Structure Determination and Refinement.  The Matthews number (22) 
suggested that the asymmetric unit contains two monomers with solvent content of 
45%.  BLAST searches (23) showed that ZmTHI1 is about 85% identical to AtTHI1 
(PDB 1RP0).  Molecular replacement was carried out with the dimer of AtTHI1 as a 
search model with all water and ligand atoms removed.  The Crystallography and 
NMR systems (CNS) program suite (24) was used to calculate the rotation and 
translation functions with a 4 Å resolution cutoff.  All model building was manually 
done using the computer program COOT (25).  The rounds of refinements were 
performed using REFMAC (22) and involved successive rounds of TLS and restrained 
refinement and model rebuilding.  Tight non-crystallographic symmetry restraints 
(NCS) were used during the initial rounds and were gradually relaxed during the final 
stages of the refinement.  Two-fold NCS averaged electron density maps and averaged 
composite omit maps were used for all stages of model building.  The ligand 
parameter and topology files were generated using PRODRG server (26). 
The V211A dataset showed ~35% merohedral twinning predicted by the 
program Xtriage in PHENIX suite (27).  As a result, refinements were performed 
using REFMAC under the correct twin operator and few rounds gave reasonable 
R/Rfree.  A summary of the refinement statistics is shown in Table 3.2. 
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Table 3.2.  Refinement statistics. 
 
 
 
Wild type 
ZmTHI1 
V211A 
ZmTHI1 
Resolution (Å) 2.5 2.04 
No of protein atoms 4160 3984 
No of water atoms 441 234 
No of ligand atoms 76 - 
RMSD 
Bonds (Å) 
Angles (deg) 
 
0.008 
1.156 
 
0.007 
1.144 
R factor a (%) 21.8 16.3 
Rfree b (%) 26.4 21.7 
Ramachandran plot 
Most favored (%) 
Additional allowed (%) 
Generously allowed (%) 
Disallowed (%) 
 
 
93.9 
5.8 
0.3 
0.0 
 
94.1 
5.6 
0.3 
0.0 
0.0 
  
aR factor = ∑hklFobs − kFcal/ ∑hklFobswhere Fobs and Fcal are observed and 
calculated structure factors, respectively.  b For Rfree the sum is extended over a subset 
of reflections (5%) excluded from all stages of refinement. 
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HPLC Analysis of ZmTHI1 and its Mutants for Associated Metabolites.  HPLC 
analyses of the bound metabolites were performed using a Supelco LC-18 (150x4.6 
mm, 3 µm ID) reverse phase column.  HPLC analyses were carried out in an Agilent 
1200 instrument equipped with an inline diode-array detector.  The enzyme was 
denatured by heat (100 °C, 60 s) and the reaction mixtures were rapidly cooled on ice. 
The precipitated protein was removed by centrifugation and the supernatant was 
filtered through a 10 kDa MWCO filter (Microcon YM-10, Millipore).  100 µL of the 
filtrate was analyzed by reversed phase HPLC.  The following linear gradient was 
used at 1 mL/min flow rate (solvent A is water, solvent B is 100 mM KPi, pH 6.6, 
solvent C is methanol): 0 min 100% B, 3 min 10% A 90% B, 10 min 25% A 60% B 
15% C, 14 min 25% A 60% B 15% C, 19 min 30% A 40% B 30% C, 21 min 100% B, 
30 min 100% B.  The absorbance at 261 nm was monitored.  Different compounds in 
the chromatogram were identified by co-migration with ScTHI4 associated 
metabolites.  This work was performed by Dinuka Abeydeera in Prof. Tadhg Begley’s 
Laboratory.  
Expression and Purification of Metabolite Free ZmTHI1.  The wild type 
enzyme purified with bound metabolites and was in an inactive form.  In order to 
obtain the active enzyme the metabolite free ZmTHI1 was expressed and purified.  
The cell-growing minimal media was prepared by autoclaving 22.5 g of M9 minimal 
salt in 2 L solution in H2O.  25 mL of 50 % (w/v) sterilized glucose, 4 mL of 1 M 
sterilized MgSO4, 0.2 mL of 1 M sterilized CaCl2, and 60 mg/L Kanamycin were 
added to the media upon cooling.  A 20 mL overnight starter culture was used to 
inoculate 1 L M9 minimal media prepared as described above.  The cells were grown 
at 37 °C, with shaking to an OD600  of 0.6, at which point they were induced with 1 
mM IPTG.  The temperature was reduced to 15 °C and the cells were additionally 
grown for 16-18 h.  The cultures were then harvested by centrifugation at 9000 g for 
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15 min at 4 ºC using an Avanti J-251 centrifuge (Beckman) and the pellets were 
frozen at -20 ºC for future use. 
To get the metabolite free protein, three round of gel filtrations were 
performed, using a Hi-Load Superdex 200 column (26/60, Amersham), equilibrated 
with 50 mM Tris buffer (pH 8.0) and 100 mM NaCl.  The fractions containing the 
protein as evidenced by SDS gel analysis were combined and concentrated to 10 
mg/mL using an Amicon Ultra centrifugal device with a 10 kDa MWCO (Millipore).  
The protein preparation was then used to set up activity assays.  This work was 
performed by Dinuka Abeydeera in Prof. Tadhg Begley’s Laboratory.  
In vitro Reconstitution of Wild Type ZmTHI1 Activity.   To the wild type 
protein (230 µM) expressed in M9 minimal media was incubated with NAD (0.5 mM 
final concentration), glycine (0.5 mM final concentration), and freshly prepared 
Fe(NH4)2(SO4)2·6H2O (0.5 mM final concentration), in the glove box (anaerobic 
atmosphere) at room temperature.  After 1 hr, an aliquot of 100 µL from the reaction 
mixture was quenched by adding into 100 µL of 8 M guanidine hydrochloride. The 
mixture was filtered through a 10 kDa MWCO filter (Microcon YM-10, Millipore). 
An injection volume of 50 uL was analyzed by the HPLC as previously described.  
Dynamic Light Scattering Studies on ZmTHI1.  DLS studies were performed 
on wild type and mutant ZmTHI1 using the instrument Zetasizer Nano-ZS (Malvern).  
The underlying principle involves measurement of the intensity of the scattered light 
and relating that to the size of the particle.  The samples were illuminated with a red 
laser beam (660 nm) and the fluctuation of the scattering intensity was measured using 
an optical angle of 173º.  The Zetasizer software was used to calculate the size 
distribution based on intensity.  Samples were prepared in 10 mM Tris (pH 8.0), 100 
mM NaCl and 4 mM DTT (buffer 1), or 10 mM Tris (pH 8.0), 100 mM NaCl and 2 % 
β-octyl-glucoside (buffer 2).  Three different concentrations: 0.5, 1.0 and 1.5 mg/mL 
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were used for each sample.  The average diameter was then used to calculate the 
approximate molecular mass.  
Figure Preparation.  All figures were prepared using Chemdraw and PYMOL 
(28). 
Section 3.3 Results 
 Mapping of blk1 on Chromosome 3L.  The blk1 mutation was mapped to 
contig 149 of the maize agarose FPC map by linkage to SSR marker umc2152 and the 
indel marker IDP351.  A population of 686 mutants was used to fine map the mutation 
to a 0.23 cM interval delimited by CAPS marker CAPSK03 (2 recombinants) and 
CAPSN05 (1 recombinant).  This region constitutes approximately 300kb from three 
contiguous sequenced BACs.  Analysis of the sequenced region revealed seven 
candidate ORFs.  Each ORF was evaluated for sequence polymorphisms that would 
disrupt the predicted gene product.  A G to A point mutation that results in a predicted 
missense mutation from Val211 to Met211 in the encoded protein was identified in the 
thiamine biosynthetic gene (thi1_2) (GRMZM2G074097) indicating that blk1 is a 
mutant allele of thi1_2. 
Overall Structure of ZmTHI1. The crystal structure of ZmTHI1 shows that the enzyme 
exists as an octamer composed of eight identical subunits (Figure 3.3a and b).  The 
asymmetric unit contains two molecules and the homooctamer, generated through 
crystallographic symmetry.  The octameric assembly can also be viewed as a tetramer 
of dimers having a shape of bi-layered ring with flattened sides.  The inner and outer 
diameters of the ring are 30 Å and 100 Å respectively, with a thickness of 70 Å.  The 
dimeric interface has a buried surface area of 3485 Å2 with primarily hydrophobic 
interactions (29).  The main dimeric interface is formed by two long antiparallel 
helices (α4), coming from each monomer composed of residues 166-177 (Figure 
3.3c).  The only hydrogen bond between the adjacent monomers is found between 
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Ser175 and Thr172.  The second dimeric interface includes a portion of α1 from one 
monomer, composed of residues 72-77, interacting with two short antiparallel strands 
β3 (residues 155-158) and β4 (residues 160-164), mainly consisting of hydrophobic 
and Van der Waals interactions. The interfaces between the dimers have a buried 
surface area of 1000 Å2 and the interactions occur in mainly two regions involving 
two molecules of the dimer.  The residues 71-76 from α1 of chain A of one dimer 
(AB), interacts with residues 79-86, the remaining portion of α1 from chain C of the 
other dimer (CD).  The second interface includes the loop joining the strands β2 and 
β3, consisting of residues 131-134 from chain A interacting with β4 containing 
residues 220-224 from chain D the other dimeric unit.  
Monomeric Structure of ZmTHI1.  The monomeric core of ZmTHI1 shows a 
αβ fold where the centrally located six stranded mixed β sheet has the topology: 
β5↑β2↑β1↑β9↑β11↑β10↓ (Figure 3.3d).  The central sheet is flanked by a bundle of 
helices containing α4, α2, α9 and α7 on one side and an antiparallel sheet containing 
β6↑β7↓ β8↑ on the other side. The monomeric chain contains one 310 helix, 
connecting strands β7 and β8 and composed of residues 164-167.  The longest helix 
α1, consisting of residues 70-87 is found near the surface of the octameric structure. 
Seven residues in the N-terminus are found to be disordered along with twenty 
residues at the C-terminal end and thus not included in the model.    
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Figure 3.3.  Structure of ZmTHI1. (A) Cartoon representation of the quaternary 
structure of ZmTHI1 octamer viewed through central cavity. (B) Cartoon 
representation of the quaternary structure of ZmTHI1 octamer rotated 90 ° about the 
horizontal axis relative to the orientation in panel A.  Both the structures are color 
coded by monomers.  (C)  Cartoon representation of the dimeric subunit of ZmTHI1 
color coded by monomer.  The α4 helices are labeled in each monomer showing the 
main dimer interface.  (d) Cartoon representation of ZmTHI1 monomer, colored by 
secondary structural elements.  The α helices are colored in blue, β strands in green 
and loops in yellow.  The ligand is shown in ball and stick representation and colored 
in magenta.   
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Active Site of ZmTHI1.  The crystal structure of the product complex maps out 
the active site of ZmTHI1 (Figure 3.4).  The active site is located near the inner side of 
the ring structure formed by the octameric assembly.  The protein contains a signature 
Gly-Ala-Gly-Ser-Ala-Gly motif (residues 93-98) characteristic of a dinucleotide 
binding domain.  The adenine ring is stabilized by a herringbone interaction with 
Phe241.  The amide nitrogen atom and carbonyl oxygen atom of Val191 form 
hydrogen bonds with N1 and N6 of adenine.  The 2′ and 3 ′ hydroxyl groups of the 
ribose moiety are anchored in the active site by forming hydrogen bonds with the 
carboxylate group of Glu118.  The O1 from the α phosphate group is hydrogen 
bonded to the amide nitrogen atom of Gly126.  The O1 of the β phosphate group 
forms a hydrogen bond with the amide nitrogen of Ala97. 
 
 
 
 
Figure 3.4.   Stereo-diagram showing the active site of ZmTHI1.  The product ADT 
and the active site residues are shown in ball and stick representation.  The carbon 
atoms are colored in green, nitrogen in blue, oxygen in red, sulfur yellow and 
phosphorus in orange.  All residues come from the same monomer, only exception 
being Asp222* coming from the neighboring monomer.  The Fo-Fc electron density 
map contoured at 3σ is colored light blue.     
 The O2 of β phosphate is hydrogen bonded to the amide nitrogen of Met289.  
The thiazole ring also forms several hydrogen bonding interactions in the active site.  
The carboxylate moiety forms two hydrogen bonds with Arg299.  The O2 of the 
carboxylate group is also hydrogen bonded to His237.  The nitrogen atom of the 
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thiazole is hydrogen bonded to the carbonyl oxygen of Gly301.  There is a triad 
formed by Met289, Met300 and Met307 on one side of the thiazole ring whereas the 
other side is positioned near Asp222 coming from a different monomer.  Cys220, a 
conserved residue among THI4/THI1 orthologues, is found in a loop near the active 
site and did not have any electron density for the sulfur atom.  This observation 
suggests that Cys220 can act as the sulfur source of the biosynthetic reaction (Figure 
3.2). 
HPLC Analysis of ZmTHI1 Bound Metabolites.  The wild type and mutant 
proteins over-expressed in LB were analyzed for bound metabolites using HPLC at 
260 nm (Figure 3.5).  Co-migration with a standard sample of ScTHI4 was used for 
the identification of the peaks.  Three peaks were obtained for the wild type enzyme 
corresponding to the intermediates C, B and the final product A of the pathway.  The 
final product A concentration was found to be the most (based on the peak area), 
suggesting a quick conversion of the intermediates to the final product.  The mutant 
enzyme did not show any of the adenylated metabolites bound to it suggesting that the 
enzyme is inactive.  
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Figure 3.5.  HPLC analysis for bound metabolites purifying with ZmTHI1.  All traces 
represent the absorption at 260 nm, detected by a diode-array detector.  Blue trace 
represents wild-type ZmTHI1 sample whereas the green and orange traces represent 
mutant-ZmTHI1 and ScTHI4 samples respectively. 
  
HPLC Analysis of the Reconstitution of Activity.  The biochemical assays for 
reconstitution of activity showed that the wild type enzyme is active (Figure 3.6a, b).  
The formation of the keto-imine intermediate (Figure 3.2, C) was observed in presence 
of NAD and the wild-type enzyme.  However such reconstitution failed in case of the 
mutant enzyme. 
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Figure 3.6. Biochemical assays for reconstitution of enzyme activity
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Dynamic Light Scattering Studies.  The Zetasizer software was used to extract 
the information of the size distribution from the measured correlation function.  The 
size distribution curves (Figure 3.7) have the distribution of size classes in the X axis 
and relative intensity of the scattered light in Y axis and are called intensity 
distributions.  The average diameter was measured at all three concentrations for each 
sample (Table 3.3).  The molecular mass was estimated from the particle size, using an 
available standard curve.  The calculated molecular mass indicates that the wild type 
enzyme exists as an octamer in solution.  The molecular mass of the mutant predicted 
formation of an assembly larger than an octamer. 
 
Table 3.3.  Dynamic Light Scattering.  
 
 
 
Samplea d (nm)b Measured 
Molecular 
Weight 
(kDa) 
Oligomeric 
Statec 
ZmTHI1 12.08 304 octamer 
V211M 20.33 674 - 
V211A 13.62 376 octamer 
V211L 11.94 302 octamer 
V211F 15.76 472 - 
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Figure 3.7.  DLS studies on wild type and mutant ZmTHI1. 
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Site Directed Mutagenesis of ZmTHI1.  To gain further knowledge about the 
role of Val211 in thiazole formation, several other mutants were designed.  Val211 
was mutated to Ala (small side chain), Leu (medium side chain), and Phe (large side 
chain) to investigate the steric effect of this particular residue.  The biochemical assays 
with the mutants show that activity is dependent on the size of the substituent residue 
at position 211.  The profile showing the bound metabolites in the protein active site 
suggest that the V211F mutant is least active whereas the V211A mutant shows 
comparable activity to the wild type enzyme (Figure 3.8).  
DLS studies on the mutants were also performed under the same conditions.  
The V211A mutant forms an octamer whereas the other two showed larger 
hydrodynamic redius indicating the formation of a larger oligomeric assembly (Figure 
3.9).  
 
 Figure 3.8.  HPLC analyses for bound metabolites purifying with wild type and 
mutant ZmTHI1.  All traces represent the absorption at 260 nm, detected by a diode-
array detector.  Yellow trace represents wild-type ZmTHI1, blue trace V211A, green 
trace V211L, brown trace V211F and red trace represents V211M sample. 
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 Figure 3.9.  DLS studies on V211A, V211L and V211F mutants of ZmTHI1. 
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Section 3.4 Discussion 
Comparison with AtTHI1 and ScTHI4.  The structure of ZmTHI1 is the third 
example of thiazole synthase in eukaryotic thiamin thiazole biosynthetic pathway.  
The overall octameric structure (viewed as tetramer of dimer) is very similar two the 
other orthologues; AtTHI1 and ScTHI4, with the interfaces being mostly conserved.  
The monomeric fold is also very similar with significant conservation of secondary 
structural elements (Figure 3.10a).  The RMSD between ZmTHI1 and AtTHI1 is 0.3 
Å, based on alignment of 278 residues, calculated by DALI server (30) whereas the 
RMSD between ZmTHI1 and ScTHI4 is 1.3 Å, based on alignment of 272 residues.  
In all three structures the N-terminal and C-terminal tails are disordered.  A few subtle 
structural differences were observed between the plant and fungal thiazole synthases, 
mostly involving the loop regions.  An insertion of about 15 mostly hydrophilic 
residues (212-230), in ScTHI4 in the loop connecting β8 and β9.  However sequence 
alignment reveals that this loop is absent in most of the THI4/THI1 orthologues and 
probably does not play any functional role.  The other differences are observed in the 
loop connecting β6 and β7 (residues 177-185) and the loop connecting α7 and β10 
(residues 279-285), both being longer in ScTHI4.  
The active sites contain strictly conserved residues around the ligand (Table 
3.4).  However the thiazole conformation is different in AtTHI1, with the thiazole ring 
being rotated by approximately 170 ° along the C5-C6 bond (Figure 3.10b).  In 
ZmTHI1 and ScTHI4, the nitrogen of the thiazole ring forms a hydrogen bond with 
Gly301 and Gly303 respectively whereas in AtTHI1, the ring undergoes flipping, 
resulting in binding of the nitrogen to His189, Asp190 and a Zn2+ ion.  The electron 
density of the thiazole ring is poor compared to the other part of the ligand.  This 
might suggest the possibility of a mixture of different metabolites in the active site.
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Figure 3.10.  Comparison of ZmTHI1, AtTHI1 and ScTHI4.  (a) Cartoon 
representation of the superposition of the monomers of ZmTHI1 (green), AtTHI1 (red) 
and ScTHI4 (blue).    (b) Superposition of ADT bound in the active site of ZmTHI1 
(green), AtTHI1 (red) and ScTHI4 (blue).  The Zn2+ is colored in red.  The Fo-Fc 
electron density map contoured at 3σ is colored light blue. 
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Table 3.4. Comparison of the active site residues of ZmTHI1, AtTHI1 and ScTHI4. 
 
 
ZmTHI1 AtTHI1 ScTHI4 
Phe241 Phe193 Phe241 
Val191 Val143 Val170 
Glu118 Glu70 Glu97 
Gly126 Gly78 Gly105 
Ala98 Cys50 Ser76 
Cys220 Cys172 Cys205 
Ser219 Ser171 Cys204 
Met289 Met241 Met291 
Met300 Met252 Met302 
Met307 Met259 Met309 
Arg299 Arg251 Arg301 
Gly301 Gly253 Gly303 
His237 His189 His237 
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Metal Binding Site.  The active site of AtTHI1 shows the electron density for 
Zn2+ ion.  The metal is octahedrally coordinated to the nitrogen of thiazole ring, 
His189, Asp190 and two water molecules.  The side chains of corresponding residues 
have poor electron densities in ZmTHI1 and ScTHI4.  Interestingly these two residues 
are highly conserved among the THI4/THI1 orthologues.  However no catalytic 
function has been yet assigned to the Zn2+.  Recent studies on ScTHI4 have revealed 
the role of iron in full reconstitution of enzyme activity (Abhishek Chatterjee, private 
communication).  The current reconstitution assays with iron further supports its role 
in thiazole biosynthesis.  The absence of metal in the active site can be explained by 
its possible removal upon the completion of the reaction. 
Mutation of Val211.  The genetic mapping of blk1 shows that the mutation 
V211M results in the phenotype Bladekiller 1.  Val211 is a conserved residue among 
the THI4/THI1 orthologues.  The crystal structure shows that the residue is located in 
a short helix, preceding the loop (215-221) (Figure 3.11), which was shown to extend 
into the active site of another monomer, related by a crystallographic four-fold.  The 
Cys220, conserved among all THI4/THI1 orthologues, located in this loop is shown to 
be the sulfur source for thiazole formation (Abhishek Chatterjee, private 
communication).  Although being not involved in direct interaction with the ligand, 
Val211 plays a crucial role in retaining the conformation of the active site loop.  The 
replacement of the residue by larger methionine might therefore cause a 
conformational change in the loop preventing the thiazole formation.  This explains 
the observation that the mutant does not purify with any of the adenylated metabolites 
found in case of the wild type enzyme.  The failure of reconstitution using the activity 
assay also supports the loss of enzymatic activity caused the mutation. 
The other interesting feature about Val211 is that it is located in a highly 
packed interface between four monomers playing an important role in the octamer 
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formation.  It shows hydrophic interactions with Leu210 and Leu133 coming from two 
neighboring monomers.  This leads to the fact that mutation of Val211 by a bulker 
side chain like Met will cause steric clashed and hinder the formation of octameric 
interface.  In the current model Val211 was replaced by Met and all possible rotameric 
conformations resulted steric clashes with the surrounding residues.  This is further 
confirmed by dynamic light scattering studies which clearly indicated octamer 
formation for the wild type enzyme unlike the mutant. 
 
 
 
Figure 3.11.  Val211 in the interface between four monomers.  The interacting 
residues are represented in ball and stick model and color coded by monomer.  The 
active site loop following Val211 is labeled for chain A. 
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Studies on Designed Mutants.  To gain further insights towards the observed 
mutation, three mutants were designed and studied: V211A, V211L and V211F.  The 
selection of point mutations were done based on the size of the side chains, small 
(Ala), medium (Leu) and large (Phe).  The crystal structure of the V211A mutant 
revealed the octamer formation and can be described as a positive control for our 
hypothesis.  However the active site loop (215-222) is partially disordered in this 
structure suggesting some structural changes by the V211A mutation.  The side chain 
of Cys220 does not show the electron density for the sulfur atom which can be a result 
of loop disorder along with the thiazole formation.  The  difference electron density in 
the active site is very poor for the thiazole ring, predicting the possibility of a mixture 
of bound metabolites in the active site.  This can be due to the slower conversion of 
the intermediates (B and C) to the final product because of the limited availability of 
Cys220 for product formation. 
The profiles for the bound metabolites were analyzed for the mutants (Figure 
3.6).  These results show that the small side chain V211A mutant retains most of its 
activity but has higher amount of intermediates (B, C) bound suggesting a slower 
conversion to the products as compared to the wild type enzyme.  The biochemical 
profile is concomitant with the electron density in the active site.  The medium side 
chain V211L mutant shows a partially active profile with equal concentrations for all 
three adenylated metabolites (A, B and C).  The large side chain V211F mutant shows 
very little activity exhibited by the meager amount of metabolites present.   The DLS 
studies also show that octamer formation is hindered by substitution with larger 
residues at position 211 (Figure 3.7).  These results definitely suggest that mutation of 
Val211 by a larger residue disrupts thiazole biosynthesis.  These observations support 
the hypothesis that the mutation of valine to larger methionine results disruption of the 
octameric state followed by the loss of thiazole synthase activity. 
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APPENDIX 
 
 
 
 
Supplemental Table 3.1: Primers used in cloning of ZmTHI1 
 
Protein 
 
Primer sequence (5′→3′) 
Wild type 
ZmTHI1 - F 
CATATGTCCATGTCCTCCcCCAACCCGCCCTACG 
 
Wild type 
ZmTHI1 - R 
CTCGAGttaGGCGTCCACGACCTCGTCGTCC 
 
Mut 
ZmTHI1 - F 
CATATGTCCATGTCCTCCcCCAACCCGCCCTACG 
 
 
Mut 
ZmTHI1 - R 
CTCGAGttaGGCGTCCACGACCTCGTCGTCC 
 
V211A - F GGACATCGGCATGATCAGCGCgGcGCCCGGGATGAAGGCGCT
CG 
 
V211A - R CGAGCGCCTTCATCCCGGGCgCcGCGCTGATCATGCCGATGTC
C 
 
V211L - F GGACATCGGCATGATCAGCGCgcTGCCCGGGATGAAGGCGC 
 
V211L - R GCGCCTTCATCCCGGGCAgcGCGCTGATCATGCCGATGTCC 
 
V211F - F GGACATCGGCATGATCAGCGCgaTcCCCGGGATGAAGGCGC 
 
V211F - F GCGCCTTCATCCCGGGgAtcGCGCTGATCATGCCGATGTCC 
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CHAPTER 4 
GLYCAL FORMATION IN CRYSTALS OF URIDINE PHOSPHORYLASE1 
Section 4.1 Introduction 
Uridine phosphorylase (UP; EC2.4.2.3) is a key enzyme in the pyrimidine 
salvage pathway, which when appropriate precursors are available provides an 
alternative to the energy-costly de novo biosynthetic pathway.  UP catalyzes the 
reversible phosphorolysis of uridine (Urd) and 2′-deoxyuridine (dUrd), as well as their 
analogues to the respective nucleobases and ribose 1-phosphate (Scheme 4.1). UP is 
present in most organisms including prokaryotes, yeast and higher organisms 
including mammals. 
 
 
 
 
 
 
 
 
 
The three-dimensional structure of Escherichia coli UP (EcUP) has been 
previously studied in its unliganded form and in several complex forms (1-4).  The 
structure of Salmonella typhimurium UP is very similar to that of EcUP (5).  The 
bacterial enzyme exists as a hexamer comprised of six identical subunits.  The 
                                                
1 Reproduced with permission from Paul, D., O’Leary, S., Kanagalaghatta, R., Bu, W., Toms, A., 
Settembre, E., Sanders, J., Begley, T. P and  Ealick, S.E. (2010) Biochemistry 49, 3949-3509.  
Copyright 2010 American Chemical Society 
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protomer shares a common α/β fold with the nucleoside phosphorylase-I (NP-I) 
superfamily (6).  Other members of this superfamily include mammalian (7, 8) and 
bacterial (9) purine nucleoside phosphorylases (PNPs), mammalian and bacterial 
methylthioadenosine phosphorylases (10), S-
adenosylhomocysteine/methylthioadenosine nucleosidase (11) and AMP nucleosidase 
(12).  Despite the differences in amino acid sequence, oligomeric state and substrate 
specificity, the enzymes of this superfamily are characterized by a common topology. 
In mammalian cells two isoforms of UP have been identified (13).  The class 1 
isozyme is more widely distributed and has been studied in detail.  The class 2 enzyme 
shows a broader substrate specificity and substantial differences in tissue specific 
expression.  Recently the structure of class 1 human UP (hUP) was reported in 
unliganded and ligand-bound forms (14).  The human enzyme exists as a dimer with 
the same structural fold as the bacterial enzyme.  Nearly all active site residues are 
conserved between the mammalian and bacterial homologues and show similar 
protein-ligand interactions.  Structural analogy of UP to the closely related PNP, 
which has been studied extensively by isotope effects, theoretical methods and 
inhibition (15-17), suggests that the chemical reaction proceeds via an oxocarbenium 
ion-like transition state (3, Scheme 4.1). 
Carbenium ions have fascinated organic chemists for almost a century and the 
properties of this important class of reactive intermediates have been studied 
extensively (18).   In addition to the nucleoside phosphorylase reaction, carbenium 
ions have been proposed as intermediates in several enzyme-catalyzed reactions, 
including the prenyl transfer and cyclization reactions involved in terpene biosynthesis 
(19), the pyrrole tetramerization involved in porphyrin biosynthesis (20), the glycosyl 
transfer reactions involved in a wide variety of glycosylations (21), and the 
thiazole/pyrimidine coupling reaction involved in thiamin phosphate formation (22, 
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23).  With the exception of the latter reaction, evidence for enzyme-bound carbenium 
ions is always indirect, relying on substituent and isotope effects, on intermediate 
trapping and on inhibition studies.  A possible exception comes from studies on 
human CD38 (24). 
Here we present the crystal structures of EcUP treated prior to crystallization 
with 5-fluorouridine (FUrd) and sulfate, and bovine UP (bUP) treated with 5-fluoro-
2′-deoxyuridine (FdUrd) or Urd, and sulfate.  Unexpectedly, the electron density for 
each structure shows three separate species corresponding to Ura or 5-fluorouracil 
(FUra), sulfate and a ribosyl species, which was modeled as a UP-bound glycal. Our 
studies also include the determination of the structure of unliganded bUP and bUP 
treated with dUrd and sulfate.  In the latter structure the dUrd is not cleaved. 
Section 4.2 Experimental 
Chemical Reagents. M9 minimal medium, L-amino acids, magnesium sulfate, 
calcium chloride, uracil (Ura), FUra, Urd, FUrd, dUrd and FdUrd were purchased 
from Sigma-Aldrich.  Ni-NTA resin was obtained from Qiagen (Valencia, CA), MEM 
vitamin solution from Invitrogen, ampicillin, MES, ferrous sulfate, and L-
selenomethionine (SeMet) from Acros and glucose from Fisher 
Crystallization of EcUP. EcUP was expressed and purified as previously 
described (1).  EcUP was crystallized by the hanging drop method using 2 µL of 
protein solution plus 1 µL of well solution.  The protein crystallized under conditions 
very similar to those published by Burling et al (2).  The crystals grew best at 22 °C 
with the optimized mother liquor conditions of 5% - 7% PEG 4K, 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) pH 6.2 - pH 6.3, and 5% glycerol.  Crystals 
grew over 2 days to a maximum size of ~300 µm x 300 µm x 200 µm.  For complex 
crystallization, the protein was incubated with 10 mM FUrd and 10 mM ammonium 
sulfate at 4 °C for 12 h prior to crystallization.  Co-crystals grew within two days, 
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under similar conditions as the unliganded form. These crystals were rod-like with 
maximum dimensions of 25 µm x 25 µm x 500 µm.  
Cloning of bUP.  The bUP gene was amplified from the cDNA clone Mbov3 
139P15 (BacPac, http://bacpac.chori.org/) by PCR with the following primer pair: 5′-
CTG TAC TTC CAG GGT ATG GCC TCC ACC GCG GCT GAA ACG GAG-3′ and 
5′ -GAA AGC TGG GTG TCA GGC CTG CAT CAG GCG CTT C-3′.  The PCR 
product was then used as a template for another round of thermocycling with the 
following primers designed to add AttB sites to the ends of the encoded protein: 5′ -G 
GGG ACA AGT TTG TAC AAA AAA GCA GGC TCC GGA AAT CTG TAC TTC 
CAG-3′  and 5′- GGG GAC CAC TTT GTA CAA GAA AGC TGG GTG-3′.  The 
PCR product was purified and used in a Gateway BP recombination reaction with the 
Invitrogen vector pDONR221 following the manufacturer’s instructions.  Clones were 
screened by restriction digest and verified by sequencing.  A correct clone was used in 
a Gateway LR recombination reaction with the plasmid pDESTF1, which is a gateway 
adapted vector based on the pET-system from Novagen.  The plasmid pDESTF1 
encodes an N-terminal 6xHis tag and is under the control of T7lac promoter, which is 
a hybrid promotor having a T7 promotor sequence followed by a lac operator 
sequence.  Again, clones were screened by restriction digest.  A correct clone was 
named pBovUP.XF1. 
Expression and Purification of bUP.  The plasmid pBovUP.XF1 was 
transformed into BL21Star(DE3) Escherichia coli.  An overnight culture of 10 mL 
was grown in Luria-Bertani media at 37 ºC supplemented with 100 µg/mL ampicillin 
and then diluted into 1 L of medium containing 100 µg/mL ampicillin.  The cells were 
grown at 37 ºC until they reached an OD600 of 0.4, and the temperature was then 
reduced to 20 ºC.  The cells were induced with 1 mM isopropyl 1-β-D-
galactopyranoside (IPTG) when the OD600 reached 0.6 and allowed to grow overnight 
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at 15 ºC.  Cells were harvested by centrifugation at 9000g for 10 min at 4 ºC and 
stored at -20 ºC. 
 The frozen cell pellet was resuspended in 50 mL of lysate buffer (50 mM 
tris(hydroxymethyl)aminomethane (Tris), pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 
mM dithiothreitol (DTT)), and cells were subjected to sonication.  Cell debris was 
removed by centrifugation at 35000g and the clear lysate was loaded onto a Ni-NTA 
column pre-equilibrated with the lysate buffer.  After the lysate was loaded, the 
column was washed with wash buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 30 mM 
imidazole, 1 mM DTT) for about an hour.  Pure protein was eluted with 50 mM Tris, 
pH 8.0, 300 mM NaCl, 250 mM imidazole and 1 mM DTT.  The recombinant protein 
was subjected to tobacco etch virus (TEV) protease digestion, to remove the 
polyhistidine tag, in a buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM 
DTT) for 12 h. After the completion of proteolysis, as judged by SDS gel analysis, the 
protein was re-loaded onto a Ni-NTA column and the flow through was collected.  
The non-binding material was then buffer exchanged into 20 mM Tris, pH 8.0, 150 
mM NaCl.  The protein was then concentrated to 3 mg/mL using an Amicon Ultra 
centrifugal device with a 30 kDa MWCO (Millipore).  The protein was estimated to be 
greater than 95% pure based on SDS gel analysis.  The pure protein was flash frozen 
and stored at -80 ºC.   
 Expression and Purification of SeMet Bovine UP.  The expression of SeMet 
incorporated protein involves some modifications to the native protein expression 
protocol.  The plasmid pBovUP.XF1 was transformed into methionine-auxotrophic 
B834(DE3) E. coli.  A 50 mL starter culture in M9 minimal medium, containing 40 
mg/mL L-amino acids, 0.4% glucose, 2 mM magnesium sulfate, 1% MEM vitamin 
solution, 0.1 mM calcium chloride, 25 µg/mL ferrous sulfate and 100 µg/mL 
ampicillin was inoculated with a single colony and grown overnight at 37 ºC.  The 
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starter culture was grown in the presence of L-methionine to give a healthy start, as 
selenomethionine is poisonous to cells.  The starter culture was then used to inoculate 
1 L M9 minimal medium having the same composition but L selenomethionine in 
place of L-methionine.  The starter cells were washed with the M9 minimal media 
prior to inoculation to remove the normal methionine.  Induction was done using 1 
mM IPTG at OD600 of 0.6 for 12-16 hours at 15 ºC.  Cells were harvested by 
centrifugation at 9000g. 
 The purification process was the same as that for the native protein.  The pure 
protein was stored in 20 mM Tris, pH 8.0, 150 mM NaCl and 1 mM DTT.  
 For the native protein, 1 L of cell cuture produced about 20 mg of pure protein, 
while for the SeMet protein, only ~4 mg of pure protein was obtained from 1 L of 
culture. 
Crystallization of bUP.  Initial crystallization conditions of unliganded bUP 
were determined using sparse matrix screens Crystal Screen 1 and 2 (Hampton 
research) at 22 ºC using the hanging-drop vapor diffusion technique.  Several 
conditions yielded thin needle crystals that varied in quality.  The optimized 
conditions were 100 mM MES (pH 6.3), 140 mM ammonium sulfate, 18% PEG 5K 
monomethylether (PEG 5K MME). The crystals grew in 3-5 days to the size of ~200 
µm long rods.  Drops containing 1 µL of protein and 1 µL of reservoir solution were 
optimal for crystal growth.   
To obtain the ligand complexes, the enzyme was separately incubated with 5 
mM each of Urd, dUrd or FdUrd and 5 mM ammonium sulfate for 12 h prior to 
crystallization.  The rod-shaped 200-300 µm long crystals of the substrate complexes 
were obtained under very similar conditions (0.1 M MES pH 6.0-6.5, 0.2 M 
ammonium sulfate, 18-25% PEG 5K MME).  SeMet UP crystals were grown by 
hanging drop vapor diffusion at 22 ºC using a well solution containing 100 mM MES 
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(pH 6.0), 1 M LiCl and 20% PEG 6K.  In this case the needle like crystals were ~50-
80 µm long and attained their maximum size in 4-6 days. 
Data Collection and Processing.  The data for EcUP complex were measured 
at beamline 8-BM at the NE-CAT beamline at the Advanced Photon Source (APS) at 
Argonne National Laboratory using a Quantum 315 detector (Area Detector Systems 
Corporation).  Data were processed using DENZO and SCALEPACK (25).  The data 
for native bUP, SeMet bUP and the complexes were collected at the 24-ID-C station 
of the NE-CAT beamline at the APS also using a Quantum 315 detector.  A 
cryoprotectant solution of 10%-20% glycerol in the mother liquor was used to avoid 
damage during freezing. The data were indexed, integrated and scaled using the 
HKL2000 program suite (25).  The data collection and data processing statistics are 
shown in Table 4.1.
94 
Table 4.1.  Data collection statistics for UP crystals.  Values for the highest resolution 
shell are given in parentheses.   
 
 EcUP/FUra 
/glycal/SO4 
SeMet 
bUP 
bUP bUP/FU
ra 
/glycal/S
O4 
bUP/Ura 
/glycal/SO4 
bUP/dUrd 
/SO4 
Resolution 
(Å) 
2.2 3.5 2.1 2.6 2.3 2.8 
Space group P32 I4122 P41 P41212 P41212 P41212 
a (Å) 92.9 81.9 74.1 82.4 83.5 82.6 
c (Å) 145.0 266.3 266.9 258.6 260.1 259.0 
No/ASU 6 1 4 2 2 2 
Matthews 
number 
(Å3/Da) 
2.28 3.18 2.62 3.13 3.23 3.02 
Solvent 
content 
43.3% 60% 52% 60% 61% 59.4% 
Unique 
reflections 
68027 10857 91922 28368 41493 20780 
Redundancy 7.5  8.5  2.2  6.1  7.0  3.1 
Completeness 99.3 (99.0) 98.9 
(98.5) 
95.7 
(95.1) 
99.5 
(95.8) 
100 (99.9) 89 (73.8) 
Rsym * (%) 4.0 (9.6) 9.4 
(34.4) 
9.1 (36.3) 11.4 
(36.4) 
20.8 (54.9) 11.4(21.3) 
I/s 17.9 (4.6) 11.1 
(2.4) 
12.4 (2.7) 20.6 
(3.6) 
35.0(6.14) 9.5 (2.5) 
* Rsym = ΣΣi Ii−<Ι>/Σ<Ι>, where <I> is the mean intensity of the N reflections with 
intensities Ii and common indices h,k,l
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Structure Determination and Refinement of the EcUP/Ura/glycal/sulfate 
Complex. The current structure was determined by molecular replacement using the 
program CNS (26), with the previously reported native UP monomer structure 
(Protein Data Bank entry 1LX7) as the search model (2).  The refinement procedure 
included successive rounds of rigid body refinement, simulated annealing refinement, 
temperature factor refinement, and model building.  A composite omit map was 
examined to determine the active site contents and to identify alternate conformations 
of side chains.  Side chains and regions showing poorly defined peptide backbone 
electron density were then manually adjusted using the program O (27).  
Noncrystallographic symmetry (NCS) restraints improved density for some of the 
weaker regions.  The active site ligands were clearly observed in the Fo-Fc maps, but 
ligand models were not included in the refinement until later steps to minimize model 
bias.  After all protein atoms were refined, the appropriate ligand models were 
manually fit into the active site, followed by a few cycles of refinement.  The model 
was examined using CNS and PROCHECK (28).  The final refinement statistics are 
summarized in Table 4.2. 
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Table 4.2.  Refinement statistics and model building for UP datasets.  
 EcUP/FUr
a 
/glycal/S
O4 
bUP bUP/FUr
a 
/glycal/S
O4 
bUP/Ura 
/glycal/S
O4 
bUP/dUr
d 
/SO4 
Resolution (Ǻ) 2.2 2.1 2.6 2.3 2.8 
 Protein Atoms 10879 8862 4487 4483 4489 
Water Molecules 839 980 155 334 77 
Ligand Atoms 138 20 44 54 42 
RMSD 
bonds (Ǻ) 
angles (deg) 
0.018 
1.980 
0.008 
1.141 
0.008 
1.173 
0.008 
1.128 
0.007 
1.019 
R factor a (%) 19.7 17.9 16.7 18.0 18.2 
Rfree b (%) 23.9 22.5 20.5 20.8 25.0 
 
 favoured regions (%) 
89.4 93.2 91.1 91.8 88.9 
Additionally allowed 
regions (%) 
10.2 6.8 8.9 8.2 11.1 
Generously allowed 
regions (%) 
0.4 0.0 0.0 0.0 0.0 
Disallowed regions 
(%) 
0.0 0.0 0.0 0.0 0.0 
aR factor = ∑hklFobs − kFcal/ ∑hklFobswhere Fobs and Fcal are observed and 
calculated structure factors, respectively.  b For Rfree the sum is extended over a subset 
of reflections (5%) excluded from all stages of refinement. 
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Structure Determination and Refinement of bUP in Unliganded and Complex 
Forms.  To determine the structure of bUP, the single wavelength anomalous 
diffraction (SAD) method was used.  Ten Se sites out of the 12 possible sites were 
found by the program SHELXD (29). SAD phasing was done by the maximum 
likelihood program MLPHARE (30) and finally a density modified map was 
calculated using the program SHARP (31), which was used for initial model building 
at 3.5 Å.  Manual model building was done using the interactive graphic program Coot 
(32).  After a few rounds of model building, a biologically relevant crystallographic 
dimer in the SeMet UP unit cell was identified and used as the starting model for 
molecular replacement with the higher resolution native dataset.  Molecular 
replacement was carried out, with the dimer as starting model, using CNS (33) and the 
second dimer was found by translational search after fixing the first one in the unit 
cell.  Initial electron density maps were further improved by fourfold NCS averaging 
with the RAVE suit of programs (34). The refinement procedure involved successive 
rounds of rigid-body refinement, simulated-annealing refinement, temperature factor 
refinement and model rebuilding.  Initial refinement cycles were performed using 
CNS and final rounds with the PHENIX suit of programs (35). The bUP complex 
structures were determined by molecular replacement using CNS with the refined 
native bUP-dimer as the search model.  The active-site contents and alternative side 
chain conformations were determined using Fo-Fc and composite omit electron density 
maps.  Tight NCS restraints were applied during initial rounds of refinement to 
improve density in the weaker regions and were slowly relaxed during the final rounds 
of refinements.  The parameter and topology files for the ligands were generated using 
the Dundee PRDRG2 server (36) .  The sulfate ions and water molecules were 
addedand refined in CNS.  The refinement statistics are summarized in Table 4.2. 
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Analytical Ultracentrifugation.  Analytical ultracentrifugation was used to 
determine the oligomeric states of EcUP and bUP.  The software package DCDT+ 
(37) was used for data analysis.  The basic principle involves a time derivative 
approach for sedimentation velocity analysis.  The sedimentation coefficient 
distribution function is fitted to a Gaussian curve to determine concentration, 
sedimentation coefficient and diffusion coefficient of a particular species.  However 
the molecular weight determination also requires the density of the solvent, the partial 
specific volume of the protein, the viscosity of the solvent, and its temperature 
dependence in order to account for the effect of temperature and solvent on 
sedimentation property.  The program Sedenterp (38) was used for the calculation of 
those properties. 
1H NMR Spectroscopy of EcUP-catalyzed FUrd Hydrolysis in the Presence 
and Absence of Sulfate. 1H NMR spectra were obtained using a Varian INOVA 600 
MHz spectrometer and a Varian H{C/N} probe equipped with triple-axis pulsed field 
gradients. A solution (0.5 mL) was prepared containing sodium sulfate (60 mM) and 
FUrd (10 mM) in 50 mM ammonium acetate buffer (prepared with D2O, pD 7.4). 
After addition of UP (0.25 mL, final concentration 140 mM), the field-frequency lock 
and magnet Z-shims were quickly optimized. 60 spectra were then acquired at 81 s 
intervals, followed by a further 11 spectra acquired at 10 minute intervals. Each final 
spectrum was produced by averaging 16 transients. The intervals between acquisition 
of the spectra were determined by appropriately arraying the pre-acquisition delay. 
The residual solvent resonance was suppressed by presaturation. Resonances 
corresponding to the C6-H nuclei of FUrd and FUra were integrated for the individual 
spectra and used to determine the concentration of the substrate and product as a 
function of reaction time.  The concentrations were calculated at the individual time 
points as the product of the initial substrate concentration and the integral value of 
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substrate or product expressed as a fraction of the total integral value for the two 
species; no pyrimidine side products were observed during the reaction. The identity 
of the FUra product was established by comparison of its 1H NMR spectrum with that 
of a commercially available standard.  FUrd and bUP were present at concentrations 
of 5 mM and 0.01 mM respectively. 
1H NMR Spectroscopy of bUP-catalyzed FUrd Hydrolysis in the Presence and 
Absence of Sulfate. NMR spectra were acquired on a Varian INOVA 600 MHz 
instrument equipped with a Varian H{C/N} inverse-detection probe and triple-axis 
pulsed field gradients. The residual HDO resonance was suppressed by presaturation. 
Immediately prior to the experiment, the enzyme was buffer-exchanged into a freshly-
prepared buffer composed of 0.1 M ammonium bicarbonate and 0.15 M sodium 
chloride in D2O (pD 7.1). For observation of the time course of the hydrolysis 
reaction, the enzyme was added to a solution of FUrd (5 mM) in the same buffer. In a 
second experiment, potassium sulfate was also included at a final concentration of 5 
mM prior to the addition of enzyme. The final enzyme concentration was ~10 mM. 
After mixing the enzyme and substrate solutions, the instrument shims were optimized 
and the time course of the reaction was followed by acquiring 30 traces at intervals of 
three minutes over 1.5 h. Each trace was generated from an average of 32 transients. 
The spectra were processed by applying exponential multiplication (0.35 Hz) to the 
free-induction decay prior to Fourier transformation. 
Figure Preparation. All figures were prepared using ChemDraw and PyMOL 
(39). 
Section 4.3 Results 
Observation of an Unexpected Species in the Active Sites of EcUP and bUP.  
The active sites of EcUP treated with FUrd and sulfate, of bUP treated with FdUrd and 
sulfate, and of bUP treated with Urd and sulfate showed three distinct species (Figure 
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4.1a,b,c).  The three species were well separated and corresponded to Ura (or FUra), 
sulfate and a ribosyl species which we model as a glycal. The structure of bUP treated 
with dUrd and sulfate showed uncleaved nucleoside (Figure 4.1d).  
Structure of the EcUP/FUra/Gycal/Sulfate Complex.  The three dimensional 
structure of EcUP has been previously well characterized (Figure 4.2a,b) including the 
identification of key active site residues (1-4).  The active site of the enzyme can be 
divided into a base, a sugar and a phosphate binding site (Figure 4.3a).  In the EcUP 
complex, the sites are occupied by FUra, glycal and sulfate, respectively.  The binding 
site of sulfate is nearest to the protein’s surface and involves side chain interactions 
with Arg30, Arg91 and Thr94 from one subunit and Arg48 from the neighboring 
subunit.  Thr94 and Gly26 are involved in phosphate binding via main-chain 
interactions.  The 5-hydroxyl group of the glycal is stabilized by a hydrogen bonding 
interaction with N€2 of His8 coming from the other adjacent monomer and an active 
site water molecule.  The 3-hydroxy group of the glycal is stabilized by a hydrogen 
bond with the side chain of Glu198.  The O4 of FUra is hydrogen bonded to Arg168 
and an active site water molecule that is in turn hydrogen bonded to Arg223.  O2 and 
N3 form hydrogen bonds with the side-chain of Gln166.  The FUra is also involved in 
a herringbone stacking interaction with Phe162.  The 5-fluoro substituent of FUra is 
located in a hydrophobic pocket composed of residues Ile220 and Val221. 
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Figure 4.1.  Electron density for EcUP and bUP complexes. (a) Stereoview of the 
active site electron density for the EcUP/FUra/glycal/sulfate complex. (b) Stereoview 
of the active site electron density for the bUP/Ura/glycal/sulfate complex. (c) 
Stereoview of the active site electron density for the bUP/FUra/glycal/sulfate complex. 
(d) Stereoview of the active site electron density for the bUP/dUrd/sulfate complex. 
All Fo-Fc electron density maps are contoured at 3σ. C atoms are colored in green, N 
atoms in blue, O atoms in red and S atoms in yellow. 
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Figure4. 2. Structures of EcUP and bUP.  (a)  Cartoon representation of the EcUP 
hexamer color coded by monomer. (b) Cartoon representation of the EcUP monomer 
color coded by secondary structure. (c) Cartoon representation of the dimer of bovine 
UP color coded by monomer.  (d) Cartoon representation of the monomer of bUP 
colored by the secondary structural elements. The α-helices are colored blue, β-
strands are colored green and the loops are colored in yellow.  The ligands are 
represented as stick models and are shown in red. 
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Structure of bUP.  The basic fold of the nucleoside phosphorylase-I 
superfamily is conserved in bUP (Figure 4.2d).  The characteristic feature of the 
superfamily is a centrally located β-sheet, which forms a distorted β-barrel, 
surrounded by several α-helices.  The overall fold is highly similar to the recently 
published structure of hUP (14).  The sequence similarity between the human and 
bovine enzymes is 80%.  The overall three-dimensional structures are also similar, 
with an RMSD of 0.8 Å for 289 residues, and both enzymes are homodimers in the 
crystal structures.  The dimer (Figure 4.2c) has a globular shape with dimensions of 65 
× 40 × 25 Å3.  Each homodimer contains two active sites located at the dimer interface 
and utilizing residues from both chains.  The dimer interface mostly includes the N 
terminal end of one chain, consisting of residues 20-24, and a loop region of the other 
chain, containing residues 220-224. 
Structures of bUP complexes.  The active site residues of bUP are very similar 
to those of hUP (14).  In the current study, structures of three bUP complexes were 
determined: bUP/FUra/deoxyglycal/sulfate, bUP/Ura/glycal/sulfate, and 
bUP/dUrd/sulfate (Figure 4.3b, c, d).   
As was the case for EcUP, the sulfate binding site is more exposed to the 
surface than either the base or sugar binding sites.  The residues involved in sulfate 
binding are Gly59, Arg137, and Thr140 from one subunit and Arg93 from the other.  
The sulfate ion forms hydrogen bonds with the side chains of Arg137 and Arg93, the 
amide nitrogen atom of Gly59, and both the side chain and amide nitrogen atoms of 
Thr140.  Arg63 forms a hydrogen bond with sulfate in only the 
bUP/FUra/deoxyglycal/sulfate complex, but the density is very weak in the other two 
complexes, suggesting that the side chain is disordered.   
The most interesting aspect of the current study is the observation of glycals in two of 
the bUP complexes.  The glycal site is sandwiched between the Ura (FUra) and sulfate 
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binding sites in the bUP/FUra/deoxyglycal/sulfate and bUP/Ura/glycal/sulfate 
complexes.  The side chain of Glu249 forms a hydrogen bond with the 3-hydroxyl 
group of the ribose ring.  The 5-hydroxyl group hydrogen bonds with Ne2 of His35 
coming from the adjacent monomer.  An active site water molecule also makes a 
hydrogen bond with the 5-hydroxyl group.  The ribosyl moiety in the 
bUP/dUrd/sulfate complex utilizes the same interactions with the residues as the 
glycal. 
The Ura (FUra) binding site of the enzyme is located in the cleft between two 
monomers and is comparatively less exposed to the surface.  In the active site, the O4 
atom of Ura forms a hydrogen bond with Arg218 and an active site water molecule 
that is in turn hydrogen bonded to Arg274.  Residue Gln216 forms hydrogen bonds 
with O2 and N3 of the pyrimidine.  Phe212 forms herringbone packing interactions 
with the pyrimidine.  The 5-substituent of FUra inserts into a pocket formed by the 
side chains of Leu271 and Leu272.  The side chain of Ile280 is also near this 
hydrophobic pocket.  After glycal fomation, O2 of the Ura/FUra would be protonated.  
However, tautomerization would result in the keto tautomer of uracil, which is more 
stable at the crystallization pH (6-6.5).  Consequently, the keto form was modeled into 
the density and the side chain orientation of Gln216 is determined accordingly; 
however, it is also possible that because of additional stabilizing interactions in the 
active site, the enzyme-bound tautomer may not be the one favored in solution.
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Figure 4.3.  Active sites of EcUP and bUP.  (a) Stereoview of the active site of the 
cUP/FUra/glycal/sulfate complex. (b) Stereoview of the active site of the 
bUP/Ura/glycal/sulfate complex. (c) Stereoview of the active site of the 
bUP/FUra/glycal/sulfate complex.  (d) Stereoview of the active site of the 
bUP/dUrd/sufate complex.  Important surrounding residues are shown in stick 
representation. C atoms are colored in green, N atoms in blue, O atoms in red and the 
S atom in yellow.  
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Second Sulfate Binding Site.  The Fo-Fc electron density map, in the UP/Urd/sulfate 
complex structure shows a large peak suggesting the possibility of a second substrate 
binding site.  This site is located near the surface and exposed to the solvent ion 
channel.  The main interaction involves hydrogen bonds with several water molecules, 
along with Tyr126, His127 and His129.  Because the crystallization conditions 
included high sulfate concentrations, this site may be an artifact of crystallization. 
Analytical Ultracentrifugation Results. Table 3 shows the results of the data 
analysis.  The analytical ultracentrifugation data show that bUP exists as a dimer in 
solution whereas the EcUP is a hexamer. 
 
Table 4. 3.  Analytical Ultracentrifugation 
 
aThe samples were buffer exchanged in 20 mM Tris (pH 7.0) and 150 mM NaCl. 
Samplea Concentration 
(mg/mL) 
Measured 
Molecular 
Weight 
(kD) 
Calculated 
Molecular 
Weight (kD) 
Oligomeric 
State 
EcUP 2.0 181.89 163 hexamer 
EcUP 1.0 176.26 163 hexamer 
bUP 0.5 62.89 68 dimer 
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Steady-State Reaction of the UP Enzymes with FUrd under Crystallization 
Conditions.  Observation by 1H NMR of the reactions of FUrd catalyzed by bUP and 
EcUP in the presence and absence of sulfate demonstrated that, under the conditions 
used for incubation of the enzymes with fluorinated pyrimidines and sulfate prior to 
crystallization, all of the nucleoside was hydrolyzed regardless of whether sulfate was 
present (Figure 4.4).  EcUP was also capable of catalyzing the hydrolysis of Urd at a 
considerably slower rate than for FUrd (data not shown). We could not detect the 
accumulation of any products except for FUra and the four anticipated isomers of D-
ribose (limit of detection ~5%). Our enzyme preparations removed phosphate from the 
protein and the NMR spectra showed no accumulation of ribose 1-phosphate. 
Furthermore, the NMR signals for the anomeric protons of the four ribose isomers 
were doublets, indicating that solvent-derived deuterium was not incorporated at the 
C2 position of the sugar on the time scale of the experiment indicating that glycal 
formation is irreversible under the conditions employed (Scheme 4.2). 
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Figure 4.4.  Hydrolysis of Urd in the presence of UP.  (a) Reaction of FUrd occurring 
in the presence of UP. (b) Time course of the reaction catalyzed by EcUP and 
monitored by 1H NMR spectroscopy. (c) Time course of hydrolysis of FUrd catalyzed 
by bUP in the absence of sulfate or phosphate. (d) Hydrolysis of FUrd catalyzed by 
bUP in the presence of potassium sulfate (5 mM) under conditions otherwise identical 
to (c).  In the case of (c) and (d) the enzyme was present at approximately one tenth 
the concentration used for crystallization. 
Section 4.4 Discussion 
Crystal Packing for bUP. The crystal structures of unliganded, complexed and 
SeMet bUP show an interesting variation in crystal packing.  While all of the crystals 
belong to the tetragonal crystal system, and have similar unit cell dimensions, three 
different space groups are represented (Table 2.1); however, the dimeric UP structure 
remains intact in all of the three space groups.  In the SeMet UP (space group I4122), 
the asymmetric unit is a monomer and the crystallographic twofold axes generate the 
dimers.  In the UP complex structures (space group P41212), the asymmetric unit 
contains one complete dimer.  
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 The unliganded structure (space group P41) has two complete dimers in the 
asymmetric unit.  For the lower symmetry cases, the NCS mimics the crystallographic 
symmetry of the highest symmetry space group. 
Conformational Differences between Unliganded and Complexed bUP.  The 
present studies report the structures of unliganded bUP, and the 
bUP/FUra/glycal/sulfate, bUP/Ura/glycal/sulfate, and bUP/dUrd/sulfate complexes.  
Comparisons of the bUP structures show conformational changes upon ligand binding 
(Figure 4.5).  Conformational changes were also reported for hUP upon inhibitor 
binding (14).  Substrate binding is associated with movement of a loop region (277-
286), which forms a lid over the active site and results in a “closed” conformation for 
the complexes.  An interesting conformational change occurs for Tyr34 where the 
aromatic ring rotates about 90° towards the base binding site, covering the 
hydrophobic pocket.  In the unliganded bUP structure, Tyr34 is hydrogen bonded to 
Asp220 of the neighboring monomer.  However, the dimeric interaction is retained by 
repositioning of Gln279, which makes a hydrogen bond with Asp220 after Tyr34 is 
displaced.  The side chain of Ile280 moves towards the hydrophobic pocket, sealing 
the binding site, and the phenyl ring of Phe212 tilts towards the pyrimidine ring 
resulting in a herringbone stacking interaction.  Additionally, the side-chain of Arg218 
is shifted towards the active site, forming a hydrogen bond to O4 of Ura (FUra).  This 
residue and Arg274 (which hydrogen bonds to O4 through a bridging water molecule) 
stabilize the negative charge that builds up in the transition state. 
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Figure 4.5.  Stereodiagram showing the conformational change upon ligand binding in 
bUP with FUra, glycal and sulfate in the active site.  The residues showing 
conformational changes are represented with side chains.  The backbone and side 
chains are colored in cyan for the unliganded and in pink for the ligand-bound bUP. C 
atoms are colored in green, N atoms in blue, O atoms in red and S atoms in yellow for 
the ligand.  Asterisks indicate residues from an adjacent monomer 
The position of the side chain of Arg93 differs between the unliganded and complex 
structures.  In the latter case the conformation of this residue is stabilized by a 
hydrogen bond to the enzyme-bound sulfate. Overall, the side chains of residues 89-93 
rearrange to increase dimeric interactions in the complexed structures.  The side chain 
of Met109 also moves towards the ribose binding site, although this residue has 
unusually high B-factors and its positioning may be unreliable. 
Comparison of bUP and EcUP.  bUP contains 309 amino acid residues per 
monomer whereas EcUP contains 254 amino acid residues per monomer with ~27% 
sequence identity between each other.  Nevertheless, even though the sequence 
similarity is low, the basic topology is the same for the two enzymes (Figure 4.6a).  
The RMSD between the two structures is 2.8 Å for 236 residues, as calculated by the 
DALI server (40).  An interesting aspect of the mammalian enzyme is the presence of 
27 additional residues at the N terminus.  The first 14 residues are not observed in the 
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bUP crystal structure but residues 22-52 form a β-turn-β motif, capped by 310-helices 
on each side (α01β01β02α02).  One of the 310-helices is present in the bacterial 
enzyme.  A number of other structural differences are seen in loop regions.  The loop 
composed of residues 78-83 in the bovine enzyme (corresponding to residues 39-42 in 
EcUP), connecting α1 and β2, shows an insertion in the bovine enzyme.   
 
 
 
 
 
 
Figure 4.6.  Comparison of EcUP and bUP. (a) Cartoon representation of the 
superposition of the monomers of bUP (pink) and EcUP (light blue).  The ligands are 
shown in stick representation, C atoms are colored in green, N atoms in blue, O atoms 
in red and S atoms in yellow.  (b) Superposition of active sites of bUP and EcUP with 
the active site showing FUra, glycal and sulfate. N atoms are colored in blue, O atoms 
in red, S atoms in yellow and C atoms in green for bUP and grey for EcUP. Asterisks 
indicate residues from an adjacent monomer. 
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The loop joining β2 and β3 (residues 88-95 in bUP and 45-51 in EcUP) exists 
in a slightly different conformation in the bUP.  The loop (residues 99-102 in bUP and 
55-62 in EcUP) between β3 and β4 is shorter in bUP.  Another insertion occurring in 
the mammalian enzyme is the loop connecting α2 and β5 composed of residues 126-
134 (residues 84-89 in EcUP).  A structural change observed in bUP is the 
replacement ofa 310 helix in EcUP (residues 118-124) by a β-turn-β motif composed of 
residues 165-178 in bUP.  The turn followed by α4 exists has slightly different 
conformations in both the enzymes (residues 224-242 in bUP and 174-191 in EcUP).  
Despite the structural differences, the active sites are highly conserved between these 
two enzymes with very similar ligand binding residues (Table 4.4 and Figure 6b). 
A significant difference observed in the crystal structures of the two enzymes 
is that the mammalian enzyme exists as a dimer whereas the bacterial enzyme forms a 
hexamer.  These results were confirmed by analytical ultracentrifugation (Table 3).  
The bacterial hexameric assembly can be described as a trimer of dimers in which the 
active site is located at the dimer interface.  The loss of trimerization in the 
mammalian enzyme can be attributed to at least two factors.  The dimeric interactions 
in bUP are increased by additional architecture at the N terminus, offsetting the 
stability that would be gained from further trimerization.  In particular, residues 20-24 
at the N terminus interact with residues 220-224 to provide additional stabilization of 
the dimer.  Another possible factor interfering with the trimerization is the presence of 
a long loop composed of residues 167-176, which replace a 310 helix in EcUP. 
The formation of a hexameric assembly appears in general to be a 
characteristic of the microbial enzymes.  Interestingly, bacterial PNP exists as a 
hexamer organized as a trimer of dimers, and superimposes closely with the EcUP 
hexamer.  However, the mammalian PNPs form a trimers in which the three active 
sites are at the trimer interface.  While the protomers of hexagonal UP, dimeric UP, 
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hexameric PNP and trimeric PNP all have the same fold, only the latter has a 
fundamentally different oligomeric organization. 
Glycal formation at the UP Active Site.  The EcUP structure showed three 
clearly separated regions of density corresponding to FUra, a ribose derivative, and 
sulfate (Figure 1a). The C2 atom of the ribosyl species shows a tricoordinate and 
planar geometry. The distances between C1 of the ribose and N1 of FUra, and O1 of 
the sulfate are 2.93 Å and 2.87 Å, respectively, much longer than the corresponding C-
N and C-O covalent bond lengths.  We propose that this species is a glycal (or its keto 
tautomer) rather than an oxocarbenium ion because oxocarbenium ions are unlikely to 
be stable. Several examples of enzyme-catalyzed glycal formation have been reported. 
Nucleoside 2-deoxyribosyltransferase (41, 45) reversibly forms D-ribal from D-ribose 
and 2-acetamidoglucal is formed by UDP-N-acetylglucosamine 2-epimerase (42, 44). 
a-1,4-glucan lyase catalyzes the formation of glucal (43) and a glycal generated from 
sialic acid was observed in crystals of the influenza B virus neuraminidase (46).  
The interactions between the putative glycal and the active site of EcUP are 
shown in Figure 3a. O2 of FUra is positioned directly above the C2 of the glycal at a 
distance of 3.82 Å in an ideal position to function as a base for proton abstraction from 
C2’ of the substrate. The enzyme stabilizes negative charge on the C4 carbonyl group 
of the pyrimidine by hydrogen bonding to to Arg168 and to a water molecule (which 
in turn is hydrogen bonded to Arg223).  Negative charge on the C2 carbonyl group is 
stabilized by a hydrogen bond to the amide of Gln166.  
A mechanistic proposal for glycal formation is outlined in Scheme 2. In this 
mechanism, the C2 carbonyl oxygen of the fluorouracil anion 6 deprotonates the 
oxocarbenium ion 3 to give the glycal. Pyrimidine tautomerization completes the 
reaction. Several variants of this mechanism are also possible. For example, glycal 
formation could occur by a concerted syn elimination involving a late transition state 
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as described for a-1,4-glucan lyase . It is also possible that the oxocarbenium ion is 
generated from ribose and fluorouracil because most of the substrate has undergone 
hydrolysis before crystallization begins (Figure 4).  
 In the case of the bovine enzyme, both the Urd and FdUrd complex structures 
showed three clearly separated regions of density corresponding to the Ura (FUra), the 
ribosyl moiety and sulfate (Figure 1b, c).  The distances between the C1 of the glycal 
and the N1 of the Ura or FUra are 2.54 Å or 2.53 Å, respectively.  The distances 
between the glycal C1 and sulfate O1 atoms are 2.87 Å and 2.84 Å in the cases of the 
Ura/glycal/sulfate and FUra/deoxyglycal/sulfate complexes, respectively.  These 
observations suggest formation of glycal in a similar manner as described for the 
bacterial enzyme.  The key interactions for binding of the glycal in the active site of 
bUP are very similar to those in EcUP.  The action of fluorouracil as a general base for 
deprotonation of the ribose C2 is again facilitated by the stabilization of the 
fluorouracil anion by hydrogen bonds to Arg218 and to a water molecule, which in 
turn hydrogen bonds with Arg274.  The negative charge on the C2 carbonyl oxygen is 
stabilized by a hydrogen bond with the amide nitrogen of Gln216.  The glycal is 
further stabilized by hydrogen bonding interactions with the side-chains of Met248 
and Glu249.  
In the bUP/dUrd/sulfate complex, dUrd remains uncleaved (Figure 1d) and 
mimics the enzyme-substrate complex.  The sulfate ion occupies the phosphate 
binding site.  The distance between the C1′ ribose and O1 of sulfate, where the new C-
O bond would form in the case of phosphate, is 3.51 Å.   
 The trapping of the glycal was unanticipated because nothing about the room 
temperature steady state behavior of the enzyme predicted its trapping.  We used 1H 
NMR spectroscopy to follow the time course of reaction of FUrd with bUP and EcUP, 
in the presence and absence of sulfate, under conditions similar to the pre-incubation 
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used in the crystallization protocol. These experiments (Figure 4) show that both the 
mammalian and bacterial enzymes catalyze the irreversible hydrolysis of the FUrd N-
ribosyl bond, regardless of whether sulfate is present. Hydrolysis is complete within 
the period of the pre-incubation. The enzyme also catalyzes hydrolysis of Urd at a 
much slower rate under similar conditions (data not shown). We did not observe time-
dependent inhibition of the enzyme resulting from the possible accumulation of the 
trapped glycal at the active site.
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
Over the past years, macro-molecular X-ray crystallography has become a 
keystone in structural genomics, proteomics, bioinformatics, protein engineering and 
rational pharmacology.  In the presented work, macromolecular X-ray crystallography 
has been used as a tool for structural characterization of enzymes involved in thiamin 
biosynthetic and pyrimidine salvage pathways, in eukaryotes.  The structural 
information obtained at atomic resolution level elucidates the overall architecture 
along with the active site composition of a particular enzyme of interest.  The three 
dimensional structure of the enzyme with substrate, intermediate and product 
analogue, help in understanding the structural changes occurring along the reaction 
coordinate providing an insight to the mechanism of catalysis.  The structural studies 
of enzymes involved in various metabolic pathways are relevant because they can be 
considered as suitable drug targets. 
 The enzymes involved in thiamin biosynthesis have been a focus of research 
for the last decade or so (1).  The structural and biochemical studies have revealed 
most of the details of this particular pathway in bacteria.  The thiazole and pyrimidine 
fragments are synthesized in two separate routes and then combined together to form 
ThMP.  A final phosphorylation of ThMP leads to the formation of TPP, the active 
biological form of the cofactor.  Although considerable progress has been made in the 
prokaryotic system, there are still some important questions to be answered.  The 
structure of ThiH and its interaction with ThiG is still not known.  The finding that 
some organisms lack the enzymes needed in the standard pathway, opens up the 
possibility of existence of some new pathways.     
The thiamin biosynthesis in eukaryotes is still in its early stage of development 
and has a lot of unraveled questions.  The recent discovery of the structure of the 
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eukaryotic thiazole synthase ScTHI4 with the mechanistic elucidation have illustrated 
that the process is very different between bacteria and eukaryotic systems (2, 3).  The 
single enzyme converts NAD, glycine and an unknown sulfur source to an adenylated 
thiazole carboxylate (ADT).  Current experimental details have indicated that the 
sulfur  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Sequence alignment of THI4/THI1 orthologues showing the conserved 
Cystine residue. 
comes from a conserved cystine residue (Cys 205 in ScTHI4) of the enzyme (Figure 
5.1).  This shows an example where the enzyme acts as a cosubstrate (Abhishek 
Chatterjee, private communication).  However the role of THI4 in mitochondrial DNA 
repair is still not understood.  The pyrimidine biosynthesis in eukaryotes is under 
development.  THI5 has been identified as the working enzyme that generates the 
HMP moiety, utilizing pyridoxine and histidine (4).  Further research on thiamin 
biosynthetic and transport proteins will continue to reveal the remarkable chemical 
details of this essential cofactor. 
In Chapter 2, structural characterization of eukaryotic thiamin biosynthetic 
enzyme CgTHI6 has been described.  This is the first three dimensional structure of a 
bifunctional enzyme where the N-terminal domain is responsible for ligating the 
thiazole and pyrimidine fragments and the C-terminal domain has a salvage activity, 
responsible for an ATP mediated phosphorylation of ThZ-OH to ThZ-P.  The enzyme 
exists as a homohexamer forming a prolate spheroid structure where the two C-
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terminal domains form the top and bottom core of the structure, bridged by two N-
terminal domains.  The structure is also interestingly characterized by a central cavity 
accounts for the high solvent content of the prepared crystals.  Our structural studies 
reveal that the folds of the domains are very similar to the bacterial counter-parts 
along with the retention of the trimeric C-terminal and dimeric N-terminal domains as 
observed in case of corresponding bacterial enzymes, which provides some 
implication toward the role of evolution in the structure-function relationship. 
While the three dimensional structure and the active sites of each domain of 
CgTHI6 have been identified the possible coordination between the domains is still 
not clear.  The product of the C-terminal domain (ThZ-P) acting as a substrate for the 
N-terminal domain favors the formation of this bifunctinal enzyme, however there was 
no obvious channel found between those two domains of a protomer suggesting no 
possible substrate channeling.  In recently studied bifunctional enzymes the 
demonstration of substrate channeling have been a common phenomena (5-7) whereas 
in this case the substrate ThZ-P, being not labile, is transferred by diffusion from one 
active site to the other and the enhancement its local concentration is simply beneficial 
for the chemical reaction. 
The other important question raised from our current study is about the 
conversion of ADT (THI4 product) to CO2-Thz-P (THI6 substrate).  The absence of 
the adenylyl cleavage activity in CgTHI6 opens up the possibility of existence of an 
adenylyl transferase enzyme in this pathway.  The identification of the responsible 
enzyme will reveal the biochemical foundation of this essential process. 
Chapter 3 includes the structural and biochemical characterization of a 
thiazole-thiamin biosynthetic enzyme ZmTHI1.  Recent studies showed that a 
mutation in the thiazole biosynthetic gene thi1_2 results a phenotype called 
Bladekiller1 (blk1) exhibiting premature termination of influorescence and axillary 
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meristems and poor development of leaf blades.  The observed mutation involves the 
change of Val211 to Met211.  The three dimensional structure of the wild type 
enzyme has revealed the role of Val211 in structural and biochemical features of the 
enzyme.  Val211 although not involved in any direct interaction with the ligand, is 
located in a short helix, preceding the active site loop containing residues 215-221.  A 
mutation of this residue could possibly result the change in the loop conformation 
affecting the ligand binding.  The results of the biochemical assays further showed that 
the wild type enzyme purifies with the adenylated metabolites and the mutant does 
not.  The DLS studies have indicated that the wild type enzyme exists as an octamer 
unlike the mutation suggesting that the octamer formation is also hindered by the 
current mutation.  The mutants designed have also supported the theory that the 
thiazole synthase activity and octamer formation depends on the steric effect of the 
side chain.  However the crystal structure of the mutants will further prove our current 
theory. 
Intriguingly Cys 220, a conserved residue in the active site loop did not show 
any electron density for the sulfur atom.  This indicates the possibility of involvement 
of the enzyme as a co-substrate where Cys 220 acts as the sulfur source of the thiazole 
ring.  Although over the past few years a lot progress has been made in the eukaryotic 
thiazole synthase there are few interesting questions remaining.  The role of metal in 
the activity have been suggested for ScTHI4, however the active site shows no 
electron density for metal.  This observation could be explained by the potential 
release of the metal ion after the catalysis and product formation. 
The second pathway, presented in this work is the salvage of uridine.  The 
enzymes involved in salvage pathways, providing alternatives to the energy costly de 
novo biosynthetic pathways are potential drug targets (8, 9).  The current work 
includes structural characterization of UP, that catalyzes the reversible phosphorolysis 
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of uridine to uracil and ribose 1-phosphate (or 2′-deoxyuridine to 2′-deoxyribose 1-
phosphate).  The crystal structures with different substrates show the formation of a 
glycal in the enzyme active site.  NMR time course studies elucidate that this enzyme 
can catalyze the hydrolysis of fluorinated substrates in absence of phosphate or sulfate, 
without the release of intermediate or enzyme inactivation.  The results add a 
previously unencountered motif to the body of information on glycal formation in 
active sites of the enzymes, catalyzing the cleavage of glycosyl bonds. 
Each of the above examples has touches on active arenas of structural biology 
results. The fusion of a biosynthetic enzyme and a salvage enzyme by Nature raises 
the important question of the role of evolution therein in the formation of THI6 in 
eukaryotes.   The formation of blk1 in maize caused by Val211Met mutation 
illuminates the role of the absolutely conserved amino acid residues in structure-
function interplay.  Lastly the trapping of glycal in UP active site shows that subtle 
and still poorly understood effects, occurring during the crystallization process can 
result in the trapping of intermediates yielding structures rich in mechanistic 
information.  In brief, the structural characterization of above three systems illustrates 
the contribution of macromolecular X-ray crystallography in the field of structural 
biology.                         
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